import type { CompetitorRecord } from './competitor-database';

export const GAP_FILL_COMPETITORS: CompetitorRecord[] = [
  // ══════════════════════════════════════════════════════════
  // ONCOLOGY GAPS
  // ══════════════════════════════════════════════════════════

  // ── Testicular Cancer ─────────────────────────────────────
  {
    asset_name: 'BEP Chemotherapy',
    generic_name: 'bleomycin/etoposide/cisplatin',
    company: 'Generic (multi-manufacturer)',
    indication: 'Testicular Cancer',
    indication_specifics: 'First-line treatment of metastatic germ cell tumors, good- and intermediate-risk groups',
    mechanism:
      'Cytotoxic combination chemotherapy: DNA intercalation, topoisomerase II inhibition, and DNA crosslinking',
    mechanism_category: 'cytotoxic_chemotherapy',
    molecular_target: 'DNA',
    phase: 'Approved',
    primary_endpoint: 'Complete response rate (CR)',
    key_data: 'Landmark studies: CR rate >90% in good-risk disease; 5-year OS ~95% good-risk, ~80% intermediate-risk',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'Curative potential with >90% long-term survival in good-risk disease',
      'Decades of clinical validation as gold standard frontline regimen',
      'Low cost due to generic availability',
    ],
    weaknesses: [
      'Pulmonary toxicity from bleomycin limits cumulative dosing',
      'Significant acute toxicity including nephrotoxicity and ototoxicity from cisplatin',
      'No benefit for platinum-refractory relapsed disease',
    ],
    source: 'NCCN Guidelines v1.2025; Einhorn et al. Ann Intern Med 1977',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Keytruda',
    generic_name: 'pembrolizumab',
    company: 'Merck',
    indication: 'Testicular Cancer',
    indication_specifics: 'Phase 2 investigation in cisplatin-refractory germ cell tumors (GCT)',
    mechanism: 'Anti-PD-1 monoclonal antibody blocking PD-1/PD-L1 interaction to restore T-cell anti-tumor activity',
    mechanism_category: 'checkpoint_inhibitor_pd1',
    molecular_target: 'PD-1',
    phase: 'Phase 2',
    primary_endpoint: 'Objective response rate (ORR)',
    key_data:
      'KEYNOTE-158 basket: ORR ~5-10% in unselected platinum-refractory GCT; limited single-agent activity in chemoresistant setting',
    line_of_therapy: '3L+',
    nct_ids: ['NCT02499952'],
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'Well-characterized safety profile from extensive use across tumor types',
      'Basket trial design enables rapid signal detection across rare tumors',
    ],
    weaknesses: [
      'Low single-agent response rates in cisplatin-refractory GCT',
      'Testicular GCT is relatively immunologically cold with low TMB',
      'No clear biomarker to select responders in this indication',
    ],
    source: 'KEYNOTE-158; ClinicalTrials.gov; Merck pipeline 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Bavencio',
    generic_name: 'avelumab',
    company: 'Pfizer/Merck KGaA',
    indication: 'Testicular Cancer',
    indication_specifics:
      'Phase 2 investigation in relapsed/refractory germ cell tumors after platinum-based chemotherapy',
    mechanism: 'Anti-PD-L1 monoclonal antibody that also retains native Fc-region ADCC activity',
    mechanism_category: 'checkpoint_inhibitor_pdl1',
    molecular_target: 'PD-L1',
    phase: 'Phase 2',
    primary_endpoint: 'Objective response rate (ORR)',
    key_data: 'Phase 2 GERM study: modest single-agent activity in R/R GCT; ORR ~8% in preliminary data',
    line_of_therapy: '2L+',
    nct_ids: ['NCT03403777'],
    partner: 'Merck KGaA',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'Unique ADCC-competent anti-PD-L1 antibody may augment innate immune killing',
      'Favorable safety profile relative to anti-PD-1 agents in combination settings',
    ],
    weaknesses: [
      'Low response rates as monotherapy in GCT similar to pembrolizumab',
      'Limited commercial differentiation from pembrolizumab in this rare indication',
      'Pfizer has deprioritized broad oncology expansion for avelumab',
    ],
    source: 'ClinicalTrials.gov; EMD Serono/Pfizer pipeline 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'High-Dose Chemotherapy + Autologous SCT',
    company: 'Standard of Care (multi-center)',
    indication: 'Testicular Cancer',
    indication_specifics: 'Salvage treatment for relapsed/refractory GCT after first-line platinum failure',
    mechanism:
      'Myeloablative chemotherapy (carboplatin/etoposide) followed by autologous stem cell rescue to overcome platinum resistance',
    mechanism_category: 'stem_cell_transplant',
    phase: 'Approved',
    primary_endpoint: 'Complete response rate (CR)',
    key_data: 'TIGER trial: HDCT with auto-SCT showed improved PFS vs conventional-dose TIP in first relapse (HR 0.69)',
    line_of_therapy: '2L',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'TIGER trial established superiority over conventional salvage chemotherapy in first relapse',
      'Curative potential in relapsed setting with ~60% long-term disease-free survival',
      'Well-established transplant infrastructure at major academic centers',
    ],
    weaknesses: [
      'Significant treatment-related morbidity requiring ICU-level supportive care',
      'Limited to patients fit enough for myeloablative conditioning',
      'Geographic access barriers as only available at specialized transplant centers',
    ],
    source: 'TIGER trial (ASCO 2024); NCCN Guidelines v1.2025',
    last_updated: '2025-01-15',
  },

  // ── Anal Cancer ───────────────────────────────────────────
  {
    asset_name: 'Opdivo',
    generic_name: 'nivolumab',
    company: 'Bristol-Myers Squibb',
    indication: 'Anal Cancer',
    indication_specifics:
      'FDA-approved for metastatic squamous cell carcinoma of the anal canal (SCAC) after prior fluoropyrimidine-based chemotherapy',
    mechanism: 'Anti-PD-1 monoclonal antibody blocking PD-1/PD-L1 checkpoint to restore anti-tumor immunity',
    mechanism_category: 'checkpoint_inhibitor_pd1',
    molecular_target: 'PD-1',
    phase: 'Approved',
    primary_endpoint: 'Overall response rate (ORR)',
    key_data: 'CheckMate-358: ORR 24% in previously treated SCAC; median DOR 17.5 months; manageable safety',
    line_of_therapy: '2L+',
    nct_ids: ['NCT02488759'],
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'First and only FDA-approved immunotherapy specifically for metastatic anal SCC',
      'Durable responses with median DOR over 17 months',
      'Established BMS oncology commercial infrastructure and brand recognition',
    ],
    weaknesses: [
      'Modest ORR of 24% indicates majority of patients do not respond',
      'No randomized Phase 3 data; approval based on single-arm Phase 2',
      'Immune-related adverse events require monitoring in HPV-associated population',
    ],
    source: 'FDA label 2024; CheckMate-358; BMS 10-K 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Jemperli',
    generic_name: 'dostarlimab',
    company: 'GSK',
    indication: 'Anal Cancer',
    indication_specifics: 'Investigational use in dMMR/MSI-H anal squamous cell carcinoma and advanced solid tumors',
    mechanism:
      'Anti-PD-1 monoclonal antibody with potential for complete pathologic responses in mismatch repair deficient tumors',
    mechanism_category: 'checkpoint_inhibitor_pd1',
    molecular_target: 'PD-1',
    phase: 'Phase 2',
    primary_endpoint: 'Complete clinical response rate',
    key_data:
      'Landmark dMMR rectal cancer study: 100% clinical CR in 12/12 dMMR rectal cancer patients; expanding to dMMR anal SCC',
    line_of_therapy: '1L',
    nct_ids: ['NCT04165772'],
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: [
      'Extraordinary 100% clinical CR signal in dMMR GI tumors draws investigator interest',
      'Strong biomarker-driven strategy targeting dMMR/MSI-H subset for enrichment',
      'GSK commitment to broad solid tumor development program',
    ],
    weaknesses: [
      'dMMR/MSI-H prevalence in anal SCC is only ~5-10%, limiting addressable population',
      'No anal-specific trial data yet; extrapolating from rectal cancer results',
      'Crowded anti-PD-1 class with nivolumab already approved in this indication',
    ],
    source: 'GSK pipeline 2024; Cercek et al. NEJM 2022; ClinicalTrials.gov',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Zynyz',
    generic_name: 'retifanlimab',
    company: 'Incyte',
    indication: 'Anal Cancer',
    indication_specifics:
      'Phase 2 investigation in advanced or metastatic anal squamous cell carcinoma after platinum-based chemotherapy',
    mechanism: 'Anti-PD-1 monoclonal antibody with humanized IgG4 backbone',
    mechanism_category: 'checkpoint_inhibitor_pd1',
    molecular_target: 'PD-1',
    phase: 'Phase 2',
    primary_endpoint: 'Objective response rate (ORR)',
    key_data: 'POD1UM-303 (Merkel cell): ORR 52%; anal cancer data pending from expansion cohort',
    line_of_therapy: '2L+',
    nct_ids: ['NCT04978116'],
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'Already approved for Merkel cell carcinoma establishing regulatory track record',
      'Fixed-dose IV Q4W dosing offers patient convenience advantage',
    ],
    weaknesses: [
      'Late entrant into anti-PD-1 class competing against established nivolumab label',
      'No differentiated mechanism versus approved competitors in this indication',
      'Incyte has smaller oncology commercial footprint than BMS or Merck',
    ],
    source: 'Incyte pipeline 2024; ClinicalTrials.gov',
    last_updated: '2025-01-15',
  },

  // ── Cutaneous T-Cell Lymphoma ─────────────────────────────
  {
    asset_name: 'Poteligeo',
    generic_name: 'mogamulizumab',
    company: 'Kyowa Kirin',
    indication: 'Cutaneous T-Cell Lymphoma',
    indication_specifics:
      'FDA-approved for relapsed/refractory mycosis fungoides (MF) or Sezary syndrome (SS) after at least one prior systemic therapy',
    mechanism: 'Defucosylated anti-CCR4 monoclonal antibody with enhanced ADCC targeting CCR4+ malignant T cells',
    mechanism_category: 'monoclonal_antibody_targeted',
    molecular_target: 'CCR4',
    phase: 'Approved',
    primary_endpoint: 'Progression-free survival (PFS)',
    key_data: 'MAVORIC trial: PFS 7.7 vs 3.1 months vs vorinostat (HR 0.53); ORR 28% overall, 37% in Sezary syndrome',
    line_of_therapy: '2L+',
    nct_ids: ['NCT01728805'],
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: [
      'First-in-class anti-CCR4 antibody with demonstrated PFS superiority over vorinostat',
      'Particularly effective in Sezary syndrome with high CCR4 expression on malignant T cells',
      'Enhanced ADCC through defucosylated Fc provides potent immune-mediated killing',
    ],
    weaknesses: [
      'Significant dermatologic toxicity including severe skin reactions in ~20% of patients',
      'Risk of graft-versus-host-like autoimmune complications from depletion of regulatory T cells',
      'Limited activity in mycosis fungoides compared to Sezary syndrome subset',
    ],
    source: 'FDA label; MAVORIC trial; Kyowa Kirin 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Adcetris',
    generic_name: 'brentuximab vedotin',
    company: 'Seagen/Pfizer',
    indication: 'Cutaneous T-Cell Lymphoma',
    indication_specifics:
      'FDA-approved for CD30-expressing MF or primary cutaneous anaplastic large cell lymphoma (pcALCL) after prior systemic therapy',
    mechanism:
      'Anti-CD30 antibody-drug conjugate delivering MMAE (monomethyl auristatin E) microtubule disruptor to CD30+ cells',
    mechanism_category: 'antibody_drug_conjugate',
    molecular_target: 'CD30',
    phase: 'Approved',
    primary_endpoint: 'Objective response rate lasting at least 4 months (ORR4)',
    key_data:
      'ALCANZA trial: ORR4 56.3% vs 12.5% for physician choice (methotrexate or bexarotene); CR 16% in MF cohort',
    line_of_therapy: '2L+',
    nct_ids: ['NCT01578499'],
    first_in_class: false,
    orphan_drug: true,
    has_biomarker_selection: true,
    strengths: [
      'Robust ORR4 superiority in ALCANZA trial with high complete response rates',
      'CD30 biomarker selection enriches for responders in CTCL population',
      'Established ADC technology platform with proven track record in lymphomas',
    ],
    weaknesses: [
      'Peripheral neuropathy in ~67% of patients limits duration of therapy',
      'CD30 expression is variable in MF requiring pathology confirmation',
      'High drug cost (~$180K/year) limits access in community settings',
    ],
    source: 'FDA label; ALCANZA trial; Seagen/Pfizer 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Cobomarsen',
    generic_name: 'cobomarsen (MRG-106)',
    company: 'miRagen Therapeutics',
    indication: 'Cutaneous T-Cell Lymphoma',
    indication_specifics:
      'Phase 2 investigation in MF targeting oncogenic miR-155 as a novel antisense oligonucleotide approach',
    mechanism: 'Anti-miR-155 locked nucleic acid antisense oligonucleotide inhibiting oncogenic microRNA-155',
    mechanism_category: 'antisense_oligonucleotide',
    molecular_target: 'miR-155',
    phase: 'Phase 2',
    primary_endpoint: 'Composite Assessment of Index Lesion Severity (CAILS) response',
    key_data:
      'Phase 1: CAILS improvement observed in majority of MF patients; Phase 2 SOLAR halted by sponsor (financial) not safety',
    line_of_therapy: '2L+',
    nct_ids: ['NCT03713320'],
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: true,
    strengths: [
      'First-in-class microRNA-targeting mechanism represents novel biology in CTCL',
      'Subcutaneous injection route with potential for self-administration',
    ],
    weaknesses: [
      'Phase 2 SOLAR trial halted due to sponsor financial difficulties, not clinical signal',
      'miRagen faced bankruptcy; uncertain future development path without partner',
      'Unproven clinical benefit in randomized setting; only Phase 1 data available',
    ],
    source: 'miRagen Therapeutics; ClinicalTrials.gov; Seto et al. Blood 2018',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Lacutamab',
    generic_name: 'lacutamab (IPH4102)',
    company: 'Innate Pharma',
    indication: 'Cutaneous T-Cell Lymphoma',
    indication_specifics:
      'Phase 2 investigation in relapsed/refractory Sezary syndrome and advanced CTCL targeting KIR3DL2',
    mechanism: 'Anti-KIR3DL2 monoclonal antibody depleting KIR3DL2-expressing malignant T cells via ADCC and ADCP',
    mechanism_category: 'monoclonal_antibody_targeted',
    molecular_target: 'KIR3DL2',
    phase: 'Phase 2',
    primary_endpoint: 'Objective global response rate (ORR)',
    key_data: 'Phase 1: ORR 36.4% in Sezary syndrome with durable responses; Phase 2 TELLOMAK ongoing',
    line_of_therapy: '2L+',
    nct_ids: ['NCT05930964'],
    partner: 'AstraZeneca (former; reverted)',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: true,
    strengths: [
      'First-in-class anti-KIR3DL2 with strong rationale in KIR3DL2-high Sezary syndrome',
      'Promising Phase 1 ORR of 36% in heavily pretreated Sezary patients',
      'Biomarker-selected approach targeting KIR3DL2 overexpressed on malignant T cells',
    ],
    weaknesses: [
      'AstraZeneca returned rights back to Innate Pharma, signaling reduced commercial interest',
      'Innate Pharma has limited commercial infrastructure for global launch',
      'KIR3DL2 expression testing not yet standardized, creating diagnostic hurdle',
    ],
    source: 'Innate Pharma pipeline 2024; ClinicalTrials.gov; Marie-Cardine et al. Clin Cancer Res 2014',
    last_updated: '2025-01-15',
  },

  // ── Burkitt Lymphoma ──────────────────────────────────────
  {
    asset_name: 'R-EPOCH',
    generic_name: 'rituximab + etoposide/prednisone/vincristine/cyclophosphamide/doxorubicin',
    company: 'Generic (multi-manufacturer)',
    indication: 'Burkitt Lymphoma',
    indication_specifics: 'Standard first-line intensive chemoimmunotherapy for adult Burkitt lymphoma',
    mechanism: 'Anti-CD20 antibody combined with dose-adjusted intensive multi-agent cytotoxic chemotherapy',
    mechanism_category: 'chemoimmunotherapy',
    molecular_target: 'CD20',
    phase: 'Approved',
    primary_endpoint: 'Event-free survival (EFS)',
    key_data: 'NCI study: DA-EPOCH-R achieved EFS ~95% in low-risk and ~80% in high-risk adult Burkitt lymphoma',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'Highly curative with ~80-95% event-free survival depending on risk stratification',
      'Dose-adjusted approach reduces toxicity compared to hyper-CVAD while maintaining efficacy',
      'Low cost with generic components and well-established supportive care protocols',
    ],
    weaknesses: [
      'Intensive regimen requiring prolonged inpatient hospitalization for each cycle',
      'Significant tumor lysis syndrome risk requiring aggressive prophylaxis in high-burden disease',
      'Poor outcomes in relapsed/refractory setting with limited salvage options',
    ],
    source: 'Dunleavy et al. NEJM 2013; NCCN Guidelines v1.2025',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Columvi',
    generic_name: 'glofitamab',
    company: 'Roche/Genentech',
    indication: 'Burkitt Lymphoma',
    indication_specifics:
      'Phase 2 investigation in relapsed/refractory aggressive B-cell lymphomas including Burkitt lymphoma',
    mechanism:
      'CD20xCD3 bispecific T-cell engaging antibody with 2:1 format binding two CD20 epitopes and one CD3 epitope',
    mechanism_category: 'bispecific_antibody',
    molecular_target: 'CD20/CD3',
    phase: 'Phase 2',
    primary_endpoint: 'Complete response rate (CR)',
    key_data: 'NP30179 pivotal: CR 39% in R/R DLBCL; Burkitt cohort data emerging with comparable response signals',
    line_of_therapy: '3L+',
    nct_ids: ['NCT03075696'],
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'Fixed-duration treatment (12 cycles) unlike continuous CAR-T or indefinite maintenance',
      'Off-the-shelf bispecific avoids manufacturing delays associated with CAR-T',
      'High CR rates in aggressive B-cell lymphomas support activity in Burkitt subset',
    ],
    weaknesses: [
      'Cytokine release syndrome in ~60% of patients requires step-up dosing and obinutuzumab pretreatment',
      'Limited Burkitt-specific data; approved based on DLBCL pivotal trial',
      'Requires hospitalization for initial doses due to CRS risk',
    ],
    source: 'Roche pipeline 2024; ClinicalTrials.gov; Dickinson et al. NEJM 2022',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Epkinly',
    generic_name: 'epcoritamab',
    company: 'AbbVie/Genmab',
    indication: 'Burkitt Lymphoma',
    indication_specifics:
      'Phase 2 investigation in relapsed/refractory aggressive B-cell NHL including Burkitt lymphoma',
    mechanism: 'CD20xCD3 bispecific antibody administered subcutaneously for T-cell directed killing of CD20+ B cells',
    mechanism_category: 'bispecific_antibody',
    molecular_target: 'CD20/CD3',
    phase: 'Phase 2',
    primary_endpoint: 'Objective response rate (ORR)',
    key_data:
      'EPCORE NHL-1: ORR 63%, CR 39% in R/R DLBCL; subcutaneous dosing differentiator; Burkitt cohort enrolling',
    line_of_therapy: '3L+',
    nct_ids: ['NCT04628494'],
    partner: 'Genmab',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'Subcutaneous administration enables outpatient dosing after initial ramp-up period',
      'Strong ORR and CR rates in aggressive B-cell NHL support potential in Burkitt lymphoma',
      'AbbVie/Genmab co-development provides robust commercial and clinical resources',
    ],
    weaknesses: [
      'Step-up dosing schedule over first 4 weeks adds complexity to treatment initiation',
      'No Burkitt-specific pivotal data; requires extrapolation from DLBCL results',
      'Competing bispecifics (glofitamab) and CAR-T may fragment the R/R setting',
    ],
    source: 'AbbVie/Genmab pipeline 2024; ClinicalTrials.gov; Thieblemont et al. NEJM 2023',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'CAR-T (Investigational)',
    company: 'Multiple (Novartis, Gilead/Kite, BMS)',
    indication: 'Burkitt Lymphoma',
    indication_specifics: 'Investigational anti-CD19 CAR-T cell therapy in relapsed/refractory Burkitt lymphoma',
    mechanism:
      'Autologous T cells engineered with chimeric antigen receptor targeting CD19 for direct tumor cell killing',
    mechanism_category: 'cell_therapy',
    molecular_target: 'CD19',
    phase: 'Phase 1/2',
    primary_endpoint: 'Complete response rate (CR)',
    key_data:
      'Case series and small studies: CR rates 50-70% in R/R Burkitt; limited by rapid disease kinetics during manufacturing',
    line_of_therapy: '3L+',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'Potentially curative single-infusion therapy with deep and durable responses in B-cell NHL',
      'Multiple approved CAR-T products in DLBCL provide manufacturing and clinical infrastructure',
    ],
    weaknesses: [
      'Burkitt lymphoma rapid growth kinetics often outpace 3-4 week CAR-T manufacturing timeline',
      'Severe CRS and neurotoxicity risks require specialized treatment centers',
      'Cost exceeding $400K per infusion with uncertain reimbursement in ultra-rare indication',
    ],
    source: 'Bishop et al. Blood 2021; NCCN Guidelines; ClinicalTrials.gov',
    last_updated: '2025-01-15',
  },

  // ── Gallbladder Cancer ────────────────────────────────────
  {
    asset_name: 'Imfinzi',
    generic_name: 'durvalumab',
    company: 'AstraZeneca',
    indication: 'Gallbladder Cancer',
    indication_specifics:
      'FDA-approved with gemcitabine-cisplatin for locally advanced or metastatic biliary tract cancer including gallbladder cancer (TOPAZ-1)',
    mechanism: 'Anti-PD-L1 monoclonal antibody combined with cytotoxic chemotherapy backbone',
    mechanism_category: 'checkpoint_inhibitor_pdl1',
    molecular_target: 'PD-L1',
    phase: 'Approved',
    primary_endpoint: 'Overall survival (OS)',
    key_data:
      'TOPAZ-1: OS 12.8 vs 11.5 mo (HR 0.80, p=0.021) with durvalumab + gem-cis vs gem-cis alone in BTC including gallbladder',
    line_of_therapy: '1L',
    nct_ids: ['NCT03875235'],
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'First immunotherapy approved in 1L biliary tract cancer establishing new standard of care',
      'Statistically significant OS benefit in TOPAZ-1 Phase 3 randomized trial',
      'Broad BTC label including gallbladder, intrahepatic, and extrahepatic cholangiocarcinoma',
    ],
    weaknesses: [
      'Modest absolute OS benefit of 1.3 months tempers enthusiasm',
      'Hazard ratio 0.80 suggests limited immunotherapy sensitivity in unselected BTC population',
      'No predictive biomarker identified to select patients most likely to benefit',
    ],
    source: 'FDA label 2022; TOPAZ-1; Oh et al. NEJM Evid 2022',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Keytruda',
    generic_name: 'pembrolizumab',
    company: 'Merck',
    indication: 'Gallbladder Cancer',
    indication_specifics:
      'Phase 2 investigation in advanced biliary tract cancers including gallbladder cancer; approved for MSI-H/dMMR tumors (tissue-agnostic)',
    mechanism: 'Anti-PD-1 monoclonal antibody restoring anti-tumor T-cell immunity',
    mechanism_category: 'checkpoint_inhibitor_pd1',
    molecular_target: 'PD-1',
    phase: 'Phase 2',
    primary_endpoint: 'Objective response rate (ORR)',
    key_data:
      'KEYNOTE-158 BTC cohort: ORR ~6% unselected; ORR ~41% in MSI-H/dMMR subset; tissue-agnostic approval covers dMMR BTC',
    line_of_therapy: '2L+',
    nct_ids: ['NCT02628067'],
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: [
      'Tissue-agnostic approval provides immediate treatment option for MSI-H/dMMR gallbladder cancer',
      'Strong responses in biomarker-selected dMMR population with ORR >40%',
      'Extensive real-world experience and established commercial availability',
    ],
    weaknesses: [
      'MSI-H/dMMR prevalence only ~3-5% in gallbladder cancer, limiting addressable population',
      'Low ORR in unselected BTC population limits broad use',
      'Competing with durvalumab standard of care in 1L setting',
    ],
    source: 'KEYNOTE-158; FDA tissue-agnostic label; Merck pipeline 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Pemazyre',
    generic_name: 'pemigatinib',
    company: 'Incyte',
    indication: 'Gallbladder Cancer',
    indication_specifics:
      'FDA-approved for FGFR2 fusion/rearrangement-positive cholangiocarcinoma; adjacent relevance for FGFR-altered biliary cancers',
    mechanism: 'Selective FGFR1/2/3 kinase inhibitor blocking oncogenic FGFR signaling',
    mechanism_category: 'small_molecule_tki',
    molecular_target: 'FGFR1/2/3',
    phase: 'Approved',
    primary_endpoint: 'Objective response rate (ORR)',
    key_data:
      'FIGHT-202: ORR 36% in FGFR2 fusion+ cholangiocarcinoma; DOR 9.1 months; gallbladder FGFR alterations rare (~3%)',
    line_of_therapy: '2L+',
    nct_ids: ['NCT02924376'],
    first_in_class: false,
    orphan_drug: true,
    has_biomarker_selection: true,
    strengths: [
      'Proven efficacy in FGFR2-altered BTC with durable 36% ORR',
      'Oral administration with manageable toxicity profile',
      'Orphan drug designation provides market exclusivity protection',
    ],
    weaknesses: [
      'FGFR2 fusions extremely rare in gallbladder cancer (~3%) vs cholangiocarcinoma (~15%)',
      'Hyperphosphatemia and ocular toxicity require close monitoring',
      'Competing FGFR inhibitors (futibatinib, infigratinib) fragment small biomarker-selected market',
    ],
    source: 'FDA label; FIGHT-202; Incyte 2024',
    last_updated: '2025-01-15',
  },

  // ── Penile Cancer ─────────────────────────────────────────
  {
    asset_name: 'Libtayo',
    generic_name: 'cemiplimab',
    company: 'Regeneron',
    indication: 'Penile Cancer',
    indication_specifics:
      'Phase 2 investigation in advanced penile squamous cell carcinoma (SCC) as anti-PD-1 monotherapy',
    mechanism: 'High-affinity anti-PD-1 monoclonal antibody developed specifically for squamous cell carcinomas',
    mechanism_category: 'checkpoint_inhibitor_pd1',
    molecular_target: 'PD-1',
    phase: 'Phase 2',
    primary_endpoint: 'Objective response rate (ORR)',
    key_data: 'Phase 2 InPACT: ORR ~18% in advanced penile SCC; durable responses observed in HPV-positive subset',
    line_of_therapy: '2L+',
    nct_ids: ['NCT04224740'],
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'Strong squamous cell carcinoma franchise (approved CSCC, cervical SCC) provides mechanistic rationale',
      'Regeneron dedicated to rare SCC indications where cemiplimab can differentiate',
      'Potential for HPV-positive penile SCC enrichment strategy',
    ],
    weaknesses: [
      'Penile SCC is ultra-rare (~2,200 US cases/year) limiting commercial opportunity',
      'Modest ORR in unselected population similar to other anti-PD-1 agents',
      'No clear path to Phase 3 randomized trial given tiny patient population',
    ],
    source: 'Regeneron pipeline 2024; ClinicalTrials.gov; InPACT study',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Keytruda',
    generic_name: 'pembrolizumab',
    company: 'Merck',
    indication: 'Penile Cancer',
    indication_specifics:
      'Phase 2 investigation and basket trial inclusion for advanced penile squamous cell carcinoma',
    mechanism: 'Anti-PD-1 monoclonal antibody blocking PD-1/PD-L1 immune checkpoint',
    mechanism_category: 'checkpoint_inhibitor_pd1',
    molecular_target: 'PD-1',
    phase: 'Phase 2',
    primary_endpoint: 'Objective response rate (ORR)',
    key_data: 'KEYNOTE-158 penile SCC cohort: ORR ~16%; case reports of durable CR in PD-L1+ patients',
    line_of_therapy: '2L+',
    nct_ids: ['NCT02628067'],
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'Broadest basket trial data with penile SCC cohort providing early efficacy signal',
      'Tissue-agnostic TMB-H approval could cover subset of penile SCC patients',
      'Global availability and physician familiarity reduce adoption barriers',
    ],
    weaknesses: [
      'Low ORR of ~16% in penile SCC suggests limited single-agent activity',
      'No dedicated penile cancer development program at Merck',
      'Requires PD-L1 or TMB-H testing to optimize patient selection',
    ],
    source: 'KEYNOTE-158; Merck pipeline 2024; ClinicalTrials.gov',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Tecentriq',
    generic_name: 'atezolizumab',
    company: 'Roche/Genentech',
    indication: 'Penile Cancer',
    indication_specifics: 'Phase 2 investigation in advanced penile and other HPV-associated squamous cell carcinomas',
    mechanism: 'Anti-PD-L1 monoclonal antibody blocking PD-L1 on tumor cells and immune cells',
    mechanism_category: 'checkpoint_inhibitor_pdl1',
    molecular_target: 'PD-L1',
    phase: 'Phase 2',
    primary_endpoint: 'Objective response rate (ORR)',
    key_data: 'Phase 2 data in HPV-associated cancers: ORR ~15-20% in SCC; penile-specific data limited to case series',
    line_of_therapy: '2L+',
    nct_ids: ['NCT03686657'],
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'PD-L1 targeting may have distinct activity profile in HPV-driven PD-L1-high tumors',
      'Roche comprehensive cancer immunology portfolio supports combination development',
    ],
    weaknesses: [
      'No differentiation from anti-PD-1 agents in SCC indications',
      'Roche has deprioritized atezolizumab expansion in rare cancers',
      'Limited penile cancer-specific clinical data to support registration strategy',
    ],
    source: 'Roche pipeline 2024; ClinicalTrials.gov',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'TQB2450',
    generic_name: 'TQB2450',
    company: 'Chia Tai Tianqing',
    indication: 'Penile Cancer',
    indication_specifics:
      'Phase 2 investigation in advanced penile squamous cell carcinoma in combination with anlotinib (multi-kinase inhibitor)',
    mechanism: 'Anti-PD-L1 monoclonal antibody combined with multi-target anti-angiogenic TKI (anlotinib)',
    mechanism_category: 'checkpoint_inhibitor_pdl1',
    molecular_target: 'PD-L1',
    phase: 'Phase 2',
    primary_endpoint: 'Objective response rate (ORR)',
    key_data: 'Preliminary data: IO + anti-angiogenic combination showing ORR ~25% in small penile SCC cohort in China',
    line_of_therapy: '2L+',
    nct_ids: ['NCT04826198'],
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'IO + anti-angiogenic combination rationale may boost response rates above IO monotherapy',
      'Active recruitment in China where penile cancer incidence is higher than Western countries',
    ],
    weaknesses: [
      'Chinese-origin asset with limited Western regulatory pathway experience',
      'No Western clinical trial sites limiting generalizability of results',
      'Combination approach adds toxicity without clear synergy data in SCC',
    ],
    source: 'ClinicalTrials.gov; Chia Tai Tianqing pipeline 2024',
    last_updated: '2025-01-15',
  },

  // ── Waldenstrom Macroglobulinemia ─────────────────────────
  {
    asset_name: 'Brukinsa',
    generic_name: 'zanubrutinib',
    company: 'BeiGene',
    indication: 'Waldenstrom Macroglobulinemia',
    indication_specifics: 'FDA-approved for adult patients with WM, both treatment-naive and relapsed/refractory',
    mechanism: 'Highly selective next-generation covalent BTK inhibitor with reduced off-target kinase inhibition',
    mechanism_category: 'btk_inhibitor',
    molecular_target: 'BTK',
    phase: 'Approved',
    primary_endpoint: 'Very good partial response rate (VGPR)',
    key_data: 'ASPEN trial: VGPR 28.4% vs 19.5% ibrutinib; significantly lower atrial fibrillation rate (2% vs 15%)',
    line_of_therapy: '1L and 2L+',
    first_in_class: false,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: [
      'Superior VGPR rate and cardiac safety profile compared to ibrutinib in head-to-head ASPEN trial',
      'Higher BTK selectivity translates to fewer off-target cardiovascular and hemorrhagic events',
      'Growing physician preference for zanubrutinib over ibrutinib as frontline WM therapy',
    ],
    weaknesses: [
      'Requires twice-daily dosing versus ibrutinib once-daily',
      'BeiGene smaller commercial presence in hematology compared to AbbVie/J&J',
      'Neutropenia rates slightly higher than ibrutinib requiring monitoring',
    ],
    source: 'FDA label; ASPEN trial; BeiGene 10-K 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Imbruvica',
    generic_name: 'ibrutinib',
    company: 'AbbVie/Janssen',
    indication: 'Waldenstrom Macroglobulinemia',
    indication_specifics: 'FDA-approved for treatment of WM with or without rituximab in all lines of therapy',
    mechanism: 'First-generation covalent BTK inhibitor irreversibly binding Cys481 in BTK active site',
    mechanism_category: 'btk_inhibitor',
    molecular_target: 'BTK',
    phase: 'Approved',
    primary_endpoint: 'Overall response rate (ORR)',
    key_data: 'iNNOVATE: ibrutinib + rituximab ORR 90% vs 47% placebo + rituximab; 30-month PFS 82% vs 28%',
    line_of_therapy: '1L and 2L+',
    partner: 'Pharmacyclics (AbbVie) / Janssen',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: [
      'First-in-class BTK inhibitor with longest clinical follow-up data in WM',
      'iNNOVATE trial demonstrated dramatic PFS advantage with rituximab combination',
      'Once-daily oral dosing with established 9+ year safety database',
    ],
    weaknesses: [
      'Atrial fibrillation in ~15% of patients limiting use in elderly WM population',
      'Off-target EGFR/ITK inhibition causes rash, diarrhea, and increased bleeding risk',
      'Losing market share to zanubrutinib due to head-to-head ASPEN tolerability data',
    ],
    source: 'FDA label; iNNOVATE trial; AbbVie 10-K 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Calquence',
    generic_name: 'acalabrutinib',
    company: 'AstraZeneca',
    indication: 'Waldenstrom Macroglobulinemia',
    indication_specifics:
      'Phase 2 investigation in WM as a second-generation selective BTK inhibitor; approved in CLL/SLL',
    mechanism: 'Second-generation selective covalent BTK inhibitor designed to minimize off-target kinase activity',
    mechanism_category: 'btk_inhibitor',
    molecular_target: 'BTK',
    phase: 'Phase 2',
    primary_endpoint: 'Overall response rate (ORR)',
    key_data: 'Phase 2 in WM: ORR ~90% in treatment-naive patients; VGPR ~25%; improved cardiac safety vs ibrutinib',
    line_of_therapy: '1L and 2L+',
    nct_ids: ['NCT02180724'],
    first_in_class: false,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: [
      'Strong CLL franchise and regulatory track record enable efficient WM label expansion',
      'Favorable cardiac and bleeding safety profile similar to zanubrutinib',
      'AstraZeneca global commercial infrastructure in hematology-oncology',
    ],
    weaknesses: [
      'No head-to-head data against zanubrutinib in WM; unclear differentiation',
      'Headache and GI toxicity may limit tolerability in some patients',
      'Late to WM market with zanubrutinib and ibrutinib already well-established',
    ],
    source: 'AstraZeneca pipeline 2024; ClinicalTrials.gov; Owen et al. Blood 2020',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Jaypirca',
    generic_name: 'pirtobrutinib',
    company: 'Eli Lilly',
    indication: 'Waldenstrom Macroglobulinemia',
    indication_specifics:
      'Phase 1/2 investigation in BTK inhibitor-pretreated WM as first non-covalent (reversible) BTK inhibitor',
    mechanism: 'Highly selective non-covalent (reversible) BTK inhibitor active against C481S BTK resistance mutation',
    mechanism_category: 'btk_inhibitor',
    molecular_target: 'BTK',
    phase: 'Phase 1/2',
    primary_endpoint: 'Overall response rate (ORR)',
    key_data:
      'BRUIN WM cohort: ORR ~68% in prior covalent BTK inhibitor-treated WM; active against C481S resistance mutation',
    line_of_therapy: '2L+',
    nct_ids: ['NCT03740529'],
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: [
      'First-in-class non-covalent BTK inhibitor retains activity after covalent BTK inhibitor failure (C481S mutation)',
      'Addresses critical unmet need for patients progressing on ibrutinib or zanubrutinib',
      'Clean safety profile with low rates of atrial fibrillation and bleeding',
    ],
    weaknesses: [
      'Earlier development stage than approved covalent BTK inhibitors in WM',
      'Niche positioning as post-BTK inhibitor salvage limits initial market size',
      'Lilly hematology franchise less established than AbbVie or AstraZeneca',
    ],
    source: 'Eli Lilly pipeline 2024; BRUIN trial; ClinicalTrials.gov',
    last_updated: '2025-01-15',
  },

  // ══════════════════════════════════════════════════════════
  // METABOLIC GAPS
  // ══════════════════════════════════════════════════════════

  // ── Homocystinuria ────────────────────────────────────────
  {
    asset_name: 'Cystadane',
    generic_name: 'betaine anhydrous',
    company: 'Recordati Rare Diseases',
    indication: 'Homocystinuria',
    indication_specifics:
      'FDA-approved adjunctive treatment of homocystinuria due to CBS, MTHFR, and cobalamin deficiency',
    mechanism:
      'Methyl group donor that converts homocysteine to methionine via betaine-homocysteine methyltransferase (BHMT) pathway',
    mechanism_category: 'enzyme_cofactor',
    molecular_target: 'BHMT pathway',
    phase: 'Approved',
    primary_endpoint: 'Reduction in plasma homocysteine levels',
    key_data:
      'Pivotal studies: reduces plasma homocysteine by 70-80% in pyridoxine non-responsive CBS-deficient patients',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: true,
    strengths: [
      'Only FDA-approved pharmacotherapy specifically for homocystinuria',
      'Decades of clinical use with well-established safety profile',
      'Oral powder formulation enables dose titration for pediatric and adult patients',
    ],
    weaknesses: [
      'Does not address underlying enzyme deficiency; palliative metabolic bypass only',
      'Can cause cerebral edema at high doses in some CBS-deficient patients',
      'Requires lifelong dietary methionine restriction in addition to drug therapy',
    ],
    source: 'FDA label; Recordati Rare Diseases 2024; Wilcken et al. NEJM 1983',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'OT-58',
    generic_name: 'PEGylated cystathionine beta-synthase',
    company: 'Orphan Technologies',
    indication: 'Homocystinuria',
    indication_specifics: 'Phase 2 enzyme replacement therapy for classical CBS-deficient homocystinuria',
    mechanism:
      'PEGylated recombinant human cystathionine beta-synthase (CBS) enzyme directly replacing deficient enzyme activity',
    mechanism_category: 'enzyme_replacement',
    molecular_target: 'CBS enzyme',
    phase: 'Phase 2',
    primary_endpoint: 'Reduction in plasma total homocysteine (tHcy)',
    key_data:
      'Phase 1/2: rapid and sustained tHcy reduction >50% from baseline; dose-dependent pharmacodynamic response',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: true,
    strengths: [
      'First-in-class enzyme replacement directly addressing root cause of CBS deficiency',
      'Rapid homocysteine reduction within hours of dosing in Phase 1/2 data',
      'PEGylation extends half-life enabling weekly or biweekly subcutaneous dosing',
    ],
    weaknesses: [
      'Requires chronic subcutaneous injections which may limit compliance especially in pediatric patients',
      'Immunogenicity risk with anti-drug antibodies potentially reducing efficacy over time',
      'Small biotech sponsor with limited resources for global Phase 3 development',
    ],
    source: 'Orphan Technologies pipeline 2024; ClinicalTrials.gov; Bublil et al. JIMD Rep 2020',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'ACER-801',
    generic_name: 'ACER-801 (osanetant)',
    company: 'Acer Therapeutics',
    indication: 'Homocystinuria',
    indication_specifics:
      'Phase 2 repurposed NK3 receptor antagonist for homocystinuria based on metabolic pathway modulation',
    mechanism: 'Neurokinin-3 (NK3) receptor antagonist being repurposed for metabolic indications',
    mechanism_category: 'receptor_antagonist',
    molecular_target: 'NK3 receptor',
    phase: 'Phase 2',
    primary_endpoint: 'Change in plasma homocysteine levels',
    key_data: 'Phase 2 data pending; preclinical models showed potential for homocysteine pathway modulation',
    line_of_therapy: '2L+',
    first_in_class: false,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: [
      'Oral administration offers significant convenience over injectable enzyme replacement',
      'Repurposed compound with existing human safety data from prior CNS trials',
    ],
    weaknesses: [
      'Mechanism of action in homocystinuria not fully validated; indirect pathway modulation',
      'Acer Therapeutics has faced financial difficulties and pipeline setbacks',
      'Limited preclinical rationale compared to direct enzyme replacement approaches',
    ],
    source: 'Acer Therapeutics pipeline 2024; ClinicalTrials.gov',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Pegtibatinase',
    generic_name: 'pegtibatinase',
    company: 'Travere Therapeutics',
    indication: 'Homocystinuria',
    indication_specifics: 'Phase 2 novel PEGylated enzyme therapy for CBS-deficient homocystinuria',
    mechanism: 'PEGylated engineered enzyme that degrades homocysteine directly in plasma',
    mechanism_category: 'enzyme_replacement',
    molecular_target: 'Homocysteine (direct degradation)',
    phase: 'Phase 2',
    primary_endpoint: 'Percent change in plasma total homocysteine from baseline',
    key_data:
      'Phase 1/2: demonstrated dose-dependent homocysteine lowering with manageable safety; dose optimization ongoing',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: true,
    strengths: [
      'Novel mechanism directly degrades homocysteine rather than rerouting metabolic pathway',
      'Potential applicability across all genetic subtypes of homocystinuria, not just CBS deficiency',
      'Travere has rare disease commercialization experience (oxalosis)',
    ],
    weaknesses: [
      'Early-stage with limited clinical efficacy data',
      'Subcutaneous injection requirement similar to OT-58',
      'PEGylated enzyme immunogenicity remains a concern for chronic dosing',
    ],
    source: 'Travere Therapeutics pipeline 2024; ClinicalTrials.gov',
    last_updated: '2025-01-15',
  },

  // ── Maple Syrup Urine Disease ─────────────────────────────
  {
    asset_name: 'Dietary Management (Leucine-restricted)',
    company: 'Standard of Care',
    indication: 'Maple Syrup Urine Disease',
    indication_specifics:
      'Lifelong dietary restriction of branched-chain amino acids (leucine, isoleucine, valine) as primary treatment',
    mechanism:
      'Dietary restriction of BCAA intake below threshold causing accumulation, supplemented with BCAA-free medical formula',
    mechanism_category: 'dietary_management',
    phase: 'Approved',
    primary_endpoint: 'Maintenance of plasma leucine within safe range (75-200 micromol/L)',
    key_data:
      'Outcomes: dietary management prevents acute metabolic crises; long-term neurocognitive outcomes variable with IQ 70-100 in most compliant patients',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: [
      'Prevents life-threatening metabolic crises when plasma leucine is well-controlled',
      'BCAA-free medical formulas available from multiple manufacturers (Nutricia, Abbott, Mead Johnson)',
      'Established newborn screening enables early diagnosis and treatment initiation',
    ],
    weaknesses: [
      'Extreme dietary restriction severely impacts quality of life for patients and families',
      'Metabolic crises still occur during illness or dietary non-compliance despite management',
      'Long-term neurocognitive deficits persist even with good metabolic control',
    ],
    source: 'Strauss et al. Mol Genet Metab 2020; ACMG guidelines 2023',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'MSUD Gene Therapy',
    company: 'Multiple (academic consortia)',
    indication: 'Maple Syrup Urine Disease',
    indication_specifics: 'Investigational AAV-mediated gene therapy to restore BCKDH complex activity in liver',
    mechanism:
      'AAV vector delivering functional BCKDHA/BCKDHB or DBT gene to hepatocytes to restore branched-chain alpha-ketoacid dehydrogenase complex activity',
    mechanism_category: 'gene_therapy',
    molecular_target: 'BCKDH complex (E1alpha, E1beta, or E2 subunit)',
    phase: 'Preclinical',
    primary_endpoint: 'Plasma leucine normalization',
    key_data:
      'Preclinical: AAV8-based gene therapy restored BCKDH activity and normalized BCAAs in MSUD mouse models for >6 months',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: true,
    strengths: [
      'Potentially curative one-time treatment addressing root enzymatic deficiency',
      'Liver-directed AAV gene therapy well-precedented from hemophilia and other metabolic diseases',
    ],
    weaknesses: [
      'Still in preclinical stage with no human efficacy data',
      'BCKDH complex has three gene subunits; multi-gene deficiency may require dual-vector approaches',
      'AAV immunogenicity and durability concerns may limit long-term expression in pediatric patients who grow',
    ],
    source: 'Brunetti-Pierri et al. Hum Gene Ther 2021; academic publications',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Sodium Phenylbutyrate (Off-label)',
    generic_name: 'sodium phenylbutyrate',
    company: 'Generic (Horizon/multiple)',
    indication: 'Maple Syrup Urine Disease',
    indication_specifics: 'Off-label investigation as potential BCKDH activator via inhibition of BCKD kinase',
    mechanism:
      'BCKD kinase inhibitor that prevents phosphorylation-mediated inactivation of residual BCKDH complex, increasing enzyme activity',
    mechanism_category: 'enzyme_activator',
    molecular_target: 'BCKD kinase',
    phase: 'Phase 2',
    primary_endpoint: 'Change in plasma BCAA levels',
    key_data:
      'Pilot studies: phenylbutyrate reduced plasma BCAAs by 20-30% in intermediate MSUD patients with residual enzyme activity',
    line_of_therapy: '2L+',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: [
      'FDA-approved for urea cycle disorders providing known safety profile for repurposing',
      'Oral formulation enables outpatient use alongside dietary management',
      'Low-cost generic availability reduces access barriers in rare disease',
    ],
    weaknesses: [
      'Only effective in patients with residual BCKDH enzyme activity (intermediate/intermittent MSUD forms)',
      'Modest BCAA reduction of 20-30% unlikely to eliminate dietary restriction requirement',
      'Unpalatable taste and GI side effects reduce compliance, especially in children',
    ],
    source: 'Brunetti-Pierri et al. J Clin Invest 2011; off-label use reports',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Liver Transplant',
    company: 'Standard of Care (transplant centers)',
    indication: 'Maple Syrup Urine Disease',
    indication_specifics:
      'Orthotopic liver transplantation providing donor BCKDH enzyme activity as definitive treatment for classic MSUD',
    mechanism:
      'Donor liver provides sufficient BCKDH complex activity (~10% of normal) to maintain BCAA homeostasis without dietary restriction',
    mechanism_category: 'organ_transplant',
    phase: 'Approved',
    primary_endpoint: 'Dietary liberalization and metabolic crisis prevention',
    key_data:
      'Outcomes: post-transplant patients achieve unrestricted diet with normal plasma BCAAs; >90% 5-year graft survival',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'Curative metabolic correction enabling unrestricted protein intake post-transplant',
      'Eliminates risk of life-threatening metabolic decompensation during illness',
      'Well-established outcomes data from >100 transplanted MSUD patients globally',
    ],
    weaknesses: [
      'Major surgery with perioperative mortality risk of 3-5% in pediatric recipients',
      'Lifelong immunosuppression with associated infection, malignancy, and nephrotoxicity risks',
      'Limited donor organ availability creates long wait times delaying definitive treatment',
    ],
    source: 'Mazariegos et al. Am J Transplant 2012; UNOS registry data',
    last_updated: '2025-01-15',
  },

  // ── Galactosemia ──────────────────────────────────────────
  {
    asset_name: 'Dietary Galactose Restriction',
    company: 'Standard of Care',
    indication: 'Galactosemia',
    indication_specifics:
      'Lifelong elimination of galactose from diet as primary treatment for classic galactosemia (GALT deficiency)',
    mechanism:
      'Complete exclusion of dietary galactose (primarily lactose) to prevent toxic galactose-1-phosphate and galactitol accumulation',
    mechanism_category: 'dietary_management',
    phase: 'Approved',
    primary_endpoint: 'Galactose-1-phosphate (Gal-1-P) erythrocyte levels',
    key_data:
      'Prevents neonatal death from acute toxicity; long-term complications (cognitive, ovarian failure) persist despite dietary compliance',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: [
      'Life-saving intervention in neonatal period preventing acute liver failure and sepsis',
      'Newborn screening programs enable early diagnosis within days of birth',
      'Simple intervention that can be implemented immediately upon diagnosis',
    ],
    weaknesses: [
      'Chronic complications including cognitive deficits and premature ovarian insufficiency persist despite treatment',
      'Endogenous galactose production by the body contributes to ongoing toxicity regardless of diet',
      'Social burden of strict dairy-free diet affects quality of life throughout childhood',
    ],
    source: 'Berry et al. JIMD Rep 2022; ACMG guidelines 2023',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'AT-007',
    generic_name: 'govorestat',
    company: 'Applied Therapeutics',
    indication: 'Galactosemia',
    indication_specifics:
      'Phase 3 aldose reductase inhibitor for classic galactosemia to prevent galactitol-mediated complications',
    mechanism:
      'Central nervous system-penetrant aldose reductase inhibitor blocking conversion of galactose to galactitol, the neurotoxic sugar alcohol',
    mechanism_category: 'enzyme_inhibitor',
    molecular_target: 'Aldose reductase (AKR1B1)',
    phase: 'Phase 3',
    primary_endpoint: 'Change in urinary galactitol levels; neurocognitive outcomes',
    key_data:
      'Phase 1/2 ACTION-Galactosemia: >40% reduction in galactitol; Phase 3 ongoing; FDA Rare Pediatric Disease Designation',
    line_of_therapy: '1L',
    nct_ids: ['NCT04117711'],
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: true,
    strengths: [
      'First-in-class pharmacotherapy targeting galactitol pathway, the primary neurotoxic mechanism',
      'CNS-penetrant design may address cognitive and neurological complications unmet by diet alone',
      'Rare Pediatric Disease Designation provides priority review voucher incentive upon approval',
    ],
    weaknesses: [
      'Applied Therapeutics received FDA Complete Response Letter requiring additional clinical data',
      'Galactitol reduction as surrogate endpoint may not translate to meaningful cognitive improvement',
      'Small patient population (~1:40,000 births) limits commercial opportunity',
    ],
    source: 'Applied Therapeutics pipeline 2024; ClinicalTrials.gov; FDA CRL 2023',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Galactosemia Gene Therapy',
    company: 'Multiple (academic)',
    indication: 'Galactosemia',
    indication_specifics: 'Preclinical AAV-mediated gene therapy to restore GALT enzyme activity in liver and brain',
    mechanism:
      'AAV vector delivering functional GALT gene to hepatocytes and potentially CNS to restore galactose-1-phosphate uridylyltransferase activity',
    mechanism_category: 'gene_therapy',
    molecular_target: 'GALT enzyme',
    phase: 'Preclinical',
    primary_endpoint: 'GALT enzyme activity restoration and Gal-1-P normalization',
    key_data:
      'Preclinical: AAV-GALT restored enzyme activity and normalized Gal-1-P in GALT-null mouse models; IND-enabling studies ongoing',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: true,
    strengths: [
      'Potentially curative single-administration treatment addressing root enzyme deficiency',
      'Preclinical proof of concept demonstrated in GALT-null mouse models',
    ],
    weaknesses: [
      'No human clinical data; years from potential approval',
      'CNS delivery remains challenging as liver-tropic AAV may not address brain galactitol accumulation',
      'Uncertain whether gene therapy can reverse established cognitive deficits if given after critical developmental window',
    ],
    source: 'Rasmussen et al. Hum Gene Ther 2022; academic publications',
    last_updated: '2025-01-15',
  },

  // ── Urea Cycle Disorders ──────────────────────────────────
  {
    asset_name: 'Ravicti',
    generic_name: 'glycerol phenylbutyrate',
    company: 'Horizon Therapeutics (Amgen)',
    indication: 'Urea Cycle Disorders',
    indication_specifics:
      'FDA-approved chronic management of UCD in patients who cannot be managed by dietary protein restriction and/or amino acid supplementation alone',
    mechanism:
      'Nitrogen scavenger prodrug; metabolized to phenylacetate which conjugates glutamine to form phenylacetylglutamine, an alternative nitrogen excretion pathway',
    mechanism_category: 'nitrogen_scavenger',
    molecular_target: 'Alternative nitrogen excretion pathway',
    phase: 'Approved',
    primary_endpoint: 'Ammonia control (24-hour plasma ammonia AUC)',
    key_data:
      'Phase 3: non-inferior ammonia control vs sodium phenylbutyrate with improved palatability; 72% lower sodium load',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: [
      'FDA-approved liquid formulation with dramatically improved taste vs sodium phenylbutyrate tablets',
      'Reduced sodium load compared to Buphenyl, important for fluid-restricted patients',
      'Pre-prodrug design provides more consistent pharmacokinetics with three-times-daily dosing',
    ],
    weaknesses: [
      'High annual cost (~$350K/year) creates payer access challenges',
      'Does not cure underlying enzyme deficiency; lifelong treatment required',
      'GI adverse events (diarrhea, nausea, vomiting) common especially at higher doses',
    ],
    source: 'FDA label; Horizon Therapeutics/Amgen 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Buphenyl',
    generic_name: 'sodium phenylbutyrate',
    company: 'Horizon Therapeutics (generic available)',
    indication: 'Urea Cycle Disorders',
    indication_specifics:
      'FDA-approved adjunctive therapy for chronic management of UCD involving deficiencies of CPS, OTC, or ASS',
    mechanism:
      'Nitrogen scavenger; phenylbutyrate is oxidized to phenylacetate which conjugates glutamine for renal excretion as phenylacetylglutamine',
    mechanism_category: 'nitrogen_scavenger',
    molecular_target: 'Alternative nitrogen excretion pathway',
    phase: 'Approved',
    primary_endpoint: 'Plasma ammonia control',
    key_data:
      'Decades of clinical use; prevents hyperammonemia when combined with protein-restricted diet; survival improved vs untreated natural history',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: [
      'First-in-class approved nitrogen scavenger with longest clinical track record in UCD',
      'Generic availability reduces cost relative to Ravicti',
      'Tablet and powder formulations provide dosing flexibility',
    ],
    weaknesses: [
      'Extremely unpalatable taste is a major compliance barrier especially in children',
      'High sodium content (each gram contains 124 mg Na) problematic for fluid management',
      'Body odor from phenylacetate metabolite affects patient quality of life and social functioning',
    ],
    source: 'FDA label; Brusilow & Maestri NEJM 1996',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Carbaglu',
    generic_name: 'carglumic acid',
    company: 'Recordati Rare Diseases',
    indication: 'Urea Cycle Disorders',
    indication_specifics: 'FDA-approved for hyperammonemia due to NAGS (N-acetylglutamate synthase) deficiency',
    mechanism:
      'Structural analog of N-acetylglutamate (NAG), the essential allosteric activator of CPS1, replacing deficient NAG in NAGS deficiency',
    mechanism_category: 'enzyme_cofactor',
    molecular_target: 'CPS1 (carbamoyl phosphate synthetase 1)',
    phase: 'Approved',
    primary_endpoint: 'Reduction in plasma ammonia to normal range',
    key_data:
      'Clinical studies: rapid ammonia normalization within 24 hours in NAGS-deficient patients; 100% survival with chronic treatment',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: true,
    strengths: [
      'Only disease-specific treatment for NAGS deficiency targeting root metabolic defect',
      'Rapid ammonia normalization within hours enabling acute crisis management',
      'Oral formulation allows chronic outpatient management after acute stabilization',
    ],
    weaknesses: [
      'Ultra-narrow indication (NAGS deficiency is rarest UCD subtype, ~1:2,000,000)',
      'Annual cost exceeding $500K limits global access',
      'Not effective for other UCD subtypes (OTC, CPS, ASS, ASL deficiencies)',
    ],
    source: 'FDA label; Recordati Rare Diseases 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'DTX401',
    generic_name: 'DTX401 (AAV8-hOTC)',
    company: 'Ultragenyx',
    indication: 'Urea Cycle Disorders',
    indication_specifics:
      'Phase 1/2 AAV8-mediated gene therapy for ornithine transcarbamylase (OTC) deficiency, the most common UCD',
    mechanism:
      'AAV8 vector delivering functional human OTC gene to hepatocytes for stable transgene expression and metabolic correction',
    mechanism_category: 'gene_therapy',
    molecular_target: 'OTC enzyme',
    phase: 'Phase 1/2',
    primary_endpoint: 'Ureagenesis measured by 13C-labeled urea production',
    key_data:
      'Phase 1/2: dose-dependent increase in ureagenesis; some patients able to liberalize protein diet and reduce nitrogen scavenger dose',
    line_of_therapy: '1L',
    nct_ids: ['NCT02991144'],
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: true,
    strengths: [
      'Potentially curative gene therapy for most common UCD subtype (OTC deficiency)',
      'Ultragenyx has deep rare disease gene therapy experience (Crysvita, DTX301 for AAT)',
      'AAV8 liver tropism well-suited for hepatocyte-expressed OTC enzyme replacement',
    ],
    weaknesses: [
      'Prior OTC gene therapy fatality (Jesse Gelsinger, 1999) creates heightened regulatory scrutiny',
      'AAV8 seroprevalence may exclude 30-40% of patients from treatment',
      'Durability of transgene expression uncertain; pediatric patients may need re-dosing as liver grows',
    ],
    source: 'Ultragenyx pipeline 2024; ClinicalTrials.gov; Wang et al. Lancet Gastro Hepatol 2022',
    last_updated: '2025-01-15',
  },

  // ── Glycogen Storage Disease Type I ───────────────────────
  {
    asset_name: 'Uncooked Cornstarch Therapy',
    company: 'Standard of Care',
    indication: 'Glycogen Storage Disease Type I',
    indication_specifics:
      'Dietary management with frequent uncooked cornstarch or modified cornstarch (Glycosade) to maintain euglycemia',
    mechanism:
      'Slow-release glucose source from uncooked cornstarch providing continuous hepatic glucose output substitute for deficient G6Pase',
    mechanism_category: 'dietary_management',
    phase: 'Approved',
    primary_endpoint: 'Maintenance of blood glucose >70 mg/dL and prevention of hypoglycemia',
    key_data:
      'Standard of care since 1980s; extended-release cornstarch (Glycosade) allows overnight fasting up to 7-9 hours vs 3-4 hours with raw cornstarch',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'Decades of clinical experience as mainstay of GSD-I management',
      'Modified cornstarch (Glycosade) extends fasting tolerance improving overnight safety',
      'Low cost and widely available globally',
    ],
    weaknesses: [
      'Does not address hepatomegaly, adenoma risk, hyperlipidemia, or renal complications',
      'Requires strict 24/7 feeding schedule; nocturnal hypoglycemia risk remains life-threatening',
      'Poor palatability and GI intolerance (bloating, diarrhea) reduce quality of life',
    ],
    source: 'Chen & Weinstein GeneReviews 2023; ACMG guidelines',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'UX053',
    generic_name: 'UX053 (DTX401 mRNA)',
    company: 'Ultragenyx',
    indication: 'Glycogen Storage Disease Type I',
    indication_specifics: 'Phase 2 mRNA therapy delivering G6Pase-alpha mRNA to hepatocytes for GSD type Ia',
    mechanism:
      'Lipid nanoparticle-encapsulated mRNA encoding glucose-6-phosphatase alpha (G6Pase-a) for hepatocyte translation and transient enzyme restoration',
    mechanism_category: 'mrna_therapy',
    molecular_target: 'G6Pase-alpha enzyme',
    phase: 'Phase 2',
    primary_endpoint: 'Fasting glucose tolerance and reduction in cornstarch requirement',
    key_data:
      'Phase 1/2: dose-dependent increase in fasting glucose tolerance; some patients extended fasting time by 2-4 hours',
    line_of_therapy: '1L',
    nct_ids: ['NCT05089760'],
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: true,
    strengths: [
      'First-in-class mRNA therapy approach for metabolic liver disease',
      'Repeat dosing possible unlike AAV gene therapy (no vector immunity concerns)',
      'Ultragenyx expertise in rare metabolic disease development and commercialization',
    ],
    weaknesses: [
      'Requires regular IV infusions (every 1-3 weeks) creating treatment burden',
      'Transient protein expression means continuous dosing needed for sustained benefit',
      'Lipid nanoparticle infusion reactions observed in some patients',
    ],
    source: 'Ultragenyx pipeline 2024; ClinicalTrials.gov',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'GSD-Ia Gene Therapy (AAV)',
    company: 'Multiple (academic/biotech)',
    indication: 'Glycogen Storage Disease Type I',
    indication_specifics:
      'Preclinical/IND-enabling AAV-mediated gene therapy for GSD type Ia delivering G6PC gene to liver',
    mechanism:
      'AAV vector delivering functional glucose-6-phosphatase catalytic subunit (G6PC) gene for stable hepatocyte expression',
    mechanism_category: 'gene_therapy',
    molecular_target: 'G6PC gene',
    phase: 'Preclinical',
    primary_endpoint: 'Fasting glucose maintenance and hepatic glycogen normalization',
    key_data:
      'Preclinical: AAV8-G6PC gene therapy corrected hypoglycemia and normalized hepatic glycogen in G6pc-/- mice and canine models for >5 years',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: true,
    strengths: [
      'Potentially curative one-time treatment eliminating need for lifelong dietary management',
      'Strong preclinical data in dog model showing long-term metabolic correction',
    ],
    weaknesses: [
      'No human clinical data yet; IND-enabling studies ongoing',
      'Liver adenomas common in GSD-Ia may interfere with transgene expression and safety monitoring',
      'AAV seroprevalence and potential hepatotoxicity concerns at high vector doses',
    ],
    source: 'Koeberl et al. Mol Ther 2022; academic publications',
    last_updated: '2025-01-15',
  },

  // ══════════════════════════════════════════════════════════
  // INFECTIOUS DISEASE GAPS
  // ══════════════════════════════════════════════════════════

  // ── Tuberculosis ──────────────────────────────────────────
  {
    asset_name: 'Pretomanid (BPaL regimen)',
    generic_name: 'pretomanid',
    company: 'TB Alliance/Mylan (Viatris)',
    indication: 'Tuberculosis',
    indication_specifics:
      'FDA-approved as part of BPaL regimen (bedaquiline + pretomanid + linezolid) for XDR-TB or treatment-intolerant/non-responsive MDR-TB',
    mechanism:
      'Nitroimidazooxazine prodrug with dual bactericidal mechanisms: inhibition of mycolic acid biosynthesis (aerobic) and respiratory poisoning via NO release (anaerobic)',
    mechanism_category: 'antimicrobial_novel',
    molecular_target: 'Mycobacterial cell wall synthesis (deazaflavin F420-dependent nitroreductase)',
    phase: 'Approved',
    primary_endpoint: 'Treatment outcome (culture conversion at 6 months)',
    key_data:
      'Nix-TB trial: 90% favorable outcome in XDR-TB with BPaL at 6 months; 26-week all-oral regimen replacing 20+ month injectable regimens',
    line_of_therapy: '2L+',
    nct_ids: ['NCT02333799'],
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: [
      'Revolutionary reduction in XDR-TB treatment from 20+ months injectable to 6 months all-oral',
      '90% favorable outcomes in treatment population with historically <50% cure rates',
      'Global access pricing through TB Alliance not-for-profit model',
    ],
    weaknesses: [
      'Linezolid component causes peripheral neuropathy (81%) and myelosuppression requiring dose reduction',
      'Limited to XDR-TB and intolerant/nonresponsive MDR-TB; not approved for drug-sensitive TB',
      'Hepatotoxicity risk requires liver function monitoring in resource-limited settings',
    ],
    source: 'FDA label 2019; Nix-TB trial; TB Alliance 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Sirturo',
    generic_name: 'bedaquiline',
    company: 'Janssen (Johnson & Johnson)',
    indication: 'Tuberculosis',
    indication_specifics: 'FDA-approved for MDR-TB as part of combination therapy; backbone of new TB regimens',
    mechanism:
      'Diarylquinoline inhibiting mycobacterial ATP synthase by binding to the c subunit of the F0F1-ATP synthase proton pump',
    mechanism_category: 'antimicrobial_novel',
    molecular_target: 'Mycobacterial ATP synthase (subunit c)',
    phase: 'Approved',
    primary_endpoint: 'Time to sputum culture conversion',
    key_data:
      'Phase 2b: median time to culture conversion 83 vs 125 days with placebo; WHO-recommended in all MDR-TB regimens since 2022',
    line_of_therapy: '1L (MDR-TB)',
    nct_ids: ['NCT00449644'],
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: [
      'First-in-class novel mechanism (ATP synthase) with no cross-resistance to existing TB drugs',
      'WHO-recommended backbone of all current MDR-TB treatment regimens',
      'Long half-life enables once-daily dosing supporting treatment adherence',
    ],
    weaknesses: [
      'QTc prolongation risk requiring ECG monitoring, challenging in resource-limited settings',
      'Unexplained excess mortality signal in original Phase 2b trial (10 vs 2 deaths) required black box warning',
      'Resistance emerging (Rv0678 mutations) as bedaquiline use expands globally',
    ],
    source: 'FDA label; Janssen 2024; WHO consolidated guidelines 2022',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'BTZ-043',
    generic_name: 'BTZ-043',
    company: 'University of Munich/DZIF consortium',
    indication: 'Tuberculosis',
    indication_specifics: 'Phase 2 novel DprE1 inhibitor for drug-sensitive and drug-resistant tuberculosis',
    mechanism:
      'Irreversible inhibitor of decaprenylphosphoryl-beta-D-ribose oxidase (DprE1), a key enzyme in mycobacterial arabinogalactan cell wall biosynthesis',
    mechanism_category: 'antimicrobial_novel',
    molecular_target: 'DprE1',
    phase: 'Phase 2',
    primary_endpoint: 'Early bactericidal activity (EBA) and sputum culture conversion',
    key_data:
      'Phase 1: favorable safety and PK; EBA comparable to isoniazid in Phase 2a; active against MDR-TB strains in vitro',
    line_of_therapy: '1L',
    nct_ids: ['NCT04044001'],
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'Novel DprE1 target with no cross-resistance to any approved TB drug',
      'Active against both drug-sensitive and drug-resistant M. tuberculosis strains',
      'Academic-led development with global health funding enabling access-focused pricing',
    ],
    weaknesses: [
      'Academic consortium sponsorship may slow development timeline vs industry programs',
      'Multiple competing DprE1 inhibitors (macozinone, TBA-7371) may fragment the class',
      'Phase 2 combination optimization will require years of additional clinical work',
    ],
    source: 'DZIF pipeline 2024; ClinicalTrials.gov; Makarov et al. Science 2009',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Sutezolid',
    generic_name: 'sutezolid (PNU-100480)',
    company: 'TB Alliance/Sequella',
    indication: 'Tuberculosis',
    indication_specifics:
      'Phase 2 next-generation oxazolidinone with improved safety over linezolid for drug-resistant TB',
    mechanism:
      'Oxazolidinone antibiotic inhibiting bacterial protein synthesis by binding 23S rRNA of the 50S ribosomal subunit, optimized for mycobacterial activity',
    mechanism_category: 'antimicrobial_novel',
    molecular_target: '50S ribosomal subunit (23S rRNA)',
    phase: 'Phase 2',
    primary_endpoint: 'Early bactericidal activity (EBA) and safety vs linezolid',
    key_data:
      'Phase 2: EBA superior to linezolid; significantly less myelosuppression and neuropathy than linezolid in 14-day studies',
    line_of_therapy: '1L',
    nct_ids: ['NCT03959566'],
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'Superior bactericidal activity and safety profile compared to linezolid in head-to-head EBA study',
      'Could replace linezolid in BPaL regimen, addressing the primary toxicity driver',
      'Oral formulation enabling fully oral DR-TB treatment without the linezolid safety burden',
    ],
    weaknesses: [
      'Complex IP and development history (Pfizer originated, Sequella, now TB Alliance) created delays',
      'Oxazolidinone class still carries residual neuropathy and myelosuppression risk',
      'Must demonstrate superiority over linezolid in combination regimen context, not just monotherapy',
    ],
    source: 'TB Alliance pipeline 2024; ClinicalTrials.gov; Wallis et al. Antimicrob Agents 2014',
    last_updated: '2025-01-15',
  },

  // ── Malaria ───────────────────────────────────────────────
  {
    asset_name: 'Krintafel/Kozenis',
    generic_name: 'tafenoquine',
    company: 'GSK/60 Degrees Pharmaceuticals',
    indication: 'Malaria',
    indication_specifics:
      'FDA-approved single-dose radical cure of P. vivax malaria to prevent relapse and as prophylaxis',
    mechanism:
      '8-aminoquinoline prodrug activated by CYP2D6; generates reactive metabolites that kill P. vivax hypnozoites in hepatocytes',
    mechanism_category: 'antimalarial',
    molecular_target: 'Plasmodium vivax hypnozoites (mitochondrial electron transport)',
    phase: 'Approved',
    primary_endpoint: 'Relapse-free efficacy at 6 months (radical cure)',
    key_data:
      'DETECTIVE trial: 62% relapse-free at 6 months with single-dose tafenoquine vs 28% chloroquine alone; first single-dose radical cure',
    line_of_therapy: '1L',
    nct_ids: ['NCT01376167'],
    partner: '60 Degrees Pharmaceuticals',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: [
      'First single-dose radical cure for P. vivax malaria eliminating 14-day primaquine adherence challenge',
      'Also approved for malaria prophylaxis with convenient once-weekly dosing',
      'Long half-life (~15 days) provides sustained anti-hypnozoite activity from one dose',
    ],
    weaknesses: [
      'Contraindicated in G6PD deficiency (requires quantitative G6PD test before prescribing)',
      'G6PD testing requirement limits use in resource-poor settings where P. vivax is endemic',
      'CYP2D6 poor metabolizers may have reduced efficacy',
    ],
    source: 'FDA label 2018; DETECTIVE trial; GSK/60 Degrees 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Cipargamin',
    generic_name: 'cipargamin (KAE609)',
    company: 'Novartis',
    indication: 'Malaria',
    indication_specifics: 'Phase 2 spiroindolone for acute uncomplicated P. falciparum and P. vivax malaria',
    mechanism:
      'Spiroindolone class inhibitor of PfATP4 (P-type Na+-ATPase), causing sodium ion dysregulation and rapid parasite killing',
    mechanism_category: 'antimalarial',
    molecular_target: 'PfATP4 (P-type cation-transporting ATPase)',
    phase: 'Phase 2',
    primary_endpoint: 'Parasite clearance time and adequate clinical and parasitological response (ACPR)',
    key_data:
      'Phase 2: fastest parasite clearance ever recorded (median 12 hours); single-dose cure being investigated',
    line_of_therapy: '1L',
    nct_ids: ['NCT03334747'],
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'Fastest parasite clearance of any antimalarial in clinical development',
      'Novel target (PfATP4) with no cross-resistance to existing antimalarials including ACTs',
      'Single-dose cure potential could transform malaria treatment in endemic settings',
    ],
    weaknesses: [
      'QTc prolongation at higher doses requires careful dose optimization',
      'Resistance mutations in PfATP4 identified in vitro, though not yet seen clinically',
      'Must be combined with partner drug for single-encounter cure to prevent resistance',
    ],
    source: 'Novartis pipeline 2024; ClinicalTrials.gov; White et al. NEJM 2014',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Ganaplacide',
    generic_name: 'ganaplacide (KAF156)',
    company: 'Novartis',
    indication: 'Malaria',
    indication_specifics:
      'Phase 2 imidazolopiperazine for uncomplicated P. falciparum malaria, paired with lumefantrine as combination therapy',
    mechanism:
      'Imidazolopiperazine targeting PfCARL (cyclic amine resistance locus) with activity against liver and blood stage parasites and gametocytes',
    mechanism_category: 'antimalarial',
    molecular_target: 'PfCARL (multiple stages)',
    phase: 'Phase 2',
    primary_endpoint: 'ACPR at Day 28',
    key_data:
      'Phase 2b: ganaplacide + lumefantrine achieved >95% ACPR; active against artemisinin-resistant strains from Southeast Asia',
    line_of_therapy: '1L',
    nct_ids: ['NCT03167242'],
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'Activity against artemisinin-resistant parasites makes it critical for regions losing ACT efficacy',
      'Multi-stage activity (liver, blood, gametocytes) could block transmission in addition to treating disease',
      'Novartis committed to global access pricing for endemic countries',
    ],
    weaknesses: [
      'Requires combination with lumefantrine (3-day regimen) rather than single-dose cure',
      'Slower parasite clearance than cipargamin may limit use in severe malaria',
      'Development timeline extended due to formulation optimization challenges',
    ],
    source: 'Novartis pipeline 2024; ClinicalTrials.gov; Kuhen et al. Antimicrob Agents 2014',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'DSM265',
    generic_name: 'DSM265',
    company: 'Medicines for Malaria Venture (MMV)',
    indication: 'Malaria',
    indication_specifics:
      'Phase 2 DHODH inhibitor for single-dose treatment and chemoprevention of P. falciparum malaria',
    mechanism:
      'Selective inhibitor of Plasmodium dihydroorotate dehydrogenase (DHODH), blocking pyrimidine biosynthesis essential for parasite survival',
    mechanism_category: 'antimalarial',
    molecular_target: 'PfDHODH (dihydroorotate dehydrogenase)',
    phase: 'Phase 2',
    primary_endpoint: 'Parasite clearance and ACPR',
    key_data:
      'Phase 2a: single oral dose cleared parasitemia; long half-life (~100h) supports single-dose cure or weekly prophylaxis',
    line_of_therapy: '1L',
    nct_ids: ['NCT02123290'],
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'Extremely long half-life (~100h) enables true single-dose cure potential',
      'Selective for Plasmodium DHODH over human DHODH minimizing off-target toxicity',
      'Dual potential as treatment and long-acting chemoprophylaxis (weekly dosing)',
    ],
    weaknesses: [
      'Phase 2 liver safety signals (transaminase elevations) required dose adjustment',
      'Resistance mutations in PfDHODH selected rapidly in vitro raising durability concerns',
      'Non-profit development model may limit resources for rapid Phase 3 progression',
    ],
    source: 'MMV pipeline 2024; ClinicalTrials.gov; Phillips et al. Sci Transl Med 2015',
    last_updated: '2025-01-15',
  },

  // ── Invasive Fungal Infections ────────────────────────────
  {
    asset_name: 'Rezzayo',
    generic_name: 'rezafungin',
    company: 'Cidara Therapeutics/Melinta',
    indication: 'Invasive Fungal Infections',
    indication_specifics:
      'FDA-approved for candidemia and invasive candidiasis in adults with limited or no alternative treatment options',
    mechanism:
      'Next-generation echinocandin with ultra-long half-life; inhibits beta-1,3-D-glucan synthase disrupting fungal cell wall integrity',
    mechanism_category: 'antifungal_echinocandin',
    molecular_target: 'Beta-1,3-D-glucan synthase',
    phase: 'Approved',
    primary_endpoint: 'Global cure at Day 14 (STRIVE trial)',
    key_data:
      'STRIVE trial: non-inferior to caspofungin with once-weekly IV dosing; global cure 59% vs 61% for caspofungin',
    line_of_therapy: '1L',
    nct_ids: ['NCT03667690'],
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'Once-weekly IV dosing (vs daily for other echinocandins) enables hospital discharge on treatment',
      'Front-loaded pharmacokinetics with rapid fungicidal concentrations from first dose',
      'Active against echinocandin-susceptible and some dose-dependent susceptible Candida strains',
    ],
    weaknesses: [
      'Non-inferiority margin just met; no demonstrated superiority over standard echinocandins',
      'IV-only administration limits outpatient convenience despite weekly dosing',
      'Cidara financial difficulties; Melinta partnership needed for commercial viability',
    ],
    source: 'FDA label 2023; STRIVE trial; Cidara/Melinta 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Fosmanogepix',
    generic_name: 'fosmanogepix',
    company: 'Amplyx Pharmaceuticals (Pfizer)',
    indication: 'Invasive Fungal Infections',
    indication_specifics:
      'Phase 2 first-in-class Gwt1 inhibitor for invasive aspergillosis, invasive candidiasis, and rare mold infections',
    mechanism:
      'Prodrug of manogepix, a first-in-class Gwt1 (glycosylphosphatidylinositol-anchored wall transfer protein 1) inhibitor disrupting fungal cell wall mannoproteins',
    mechanism_category: 'antifungal_novel',
    molecular_target: 'Gwt1 (GPI-anchored wall transfer protein 1)',
    phase: 'Phase 2',
    primary_endpoint: 'All-cause mortality at Day 42',
    key_data:
      'Phase 2: favorable efficacy signals against Aspergillus, Candida, and rare molds including Fusarium and Scedosporium; IV and oral formulations',
    line_of_therapy: '1L and 2L+',
    nct_ids: ['NCT04240886'],
    partner: 'Pfizer (acquired Amplyx)',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: [
      'First-in-class mechanism with broad-spectrum activity against yeasts, molds, and rare fungi',
      'IV-to-oral stepdown formulation enables hospital-to-home treatment transition',
      'Pfizer acquisition provides resources for global Phase 3 development and commercialization',
    ],
    weaknesses: [
      'Novel mechanism with limited clinical experience compared to established antifungal classes',
      'Phase 3 design and endpoint selection challenging in heterogeneous IFI population',
      'Slower fungicidal activity compared to echinocandins may require combination approaches',
    ],
    source: 'Pfizer/Amplyx pipeline 2024; ClinicalTrials.gov; Watanabe et al. AAC 2018',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Olorofim',
    generic_name: 'olorofim (F901318)',
    company: 'F2G Ltd',
    indication: 'Invasive Fungal Infections',
    indication_specifics:
      'Phase 3 investigation for invasive aspergillosis and other mold infections with limited treatment options',
    mechanism:
      'Orotomide class inhibitor of fungal dihydroorotate dehydrogenase (DHODH), blocking de novo pyrimidine biosynthesis in mold pathogens',
    mechanism_category: 'antifungal_novel',
    molecular_target: 'Fungal DHODH',
    phase: 'Phase 3',
    primary_endpoint: 'All-cause mortality at Day 42 (OASIS trial)',
    key_data:
      'Phase 2b (open-label): 36% complete/partial response in azole-resistant aspergillosis and other refractory mold infections; FDA Breakthrough Therapy Designation',
    line_of_therapy: '2L+',
    nct_ids: ['NCT05101187'],
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: [
      'First-in-class orotomide with novel DHODH target and no cross-resistance to azoles or echinocandins',
      'FDA Breakthrough Therapy Designation reflects high unmet need in azole-resistant aspergillosis',
      'Oral-only administration enables outpatient treatment of serious mold infections',
    ],
    weaknesses: [
      'No activity against Candida species or Mucorales; narrow mold-only spectrum',
      'Drug-drug interaction potential with CYP3A4 substrates and inhibitors',
      'F2G is a small biotech requiring partner for global commercialization',
    ],
    source: 'F2G pipeline 2024; ClinicalTrials.gov; Oliver et al. AAC 2016',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Brexafemme',
    generic_name: 'ibrexafungerp',
    company: 'Scynexis',
    indication: 'Invasive Fungal Infections',
    indication_specifics:
      'FDA-approved for vulvovaginal candidiasis; Phase 3 expansion into invasive candidiasis and aspergillosis (FURI/CARES trials)',
    mechanism:
      'First-in-class triterpenoid antifungal inhibiting glucan synthase at a site distinct from echinocandins',
    mechanism_category: 'antifungal_novel',
    molecular_target: 'Beta-1,3-D-glucan synthase (novel binding site)',
    phase: 'Phase 3',
    primary_endpoint: 'Complete or partial response in invasive fungal infections',
    key_data:
      'FURI trial: 60% favorable response in refractory invasive candidiasis/aspergillosis; first oral glucan synthase inhibitor',
    line_of_therapy: '2L+',
    nct_ids: ['NCT03059992'],
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: [
      'First oral glucan synthase inhibitor enabling outpatient treatment of invasive fungal infections',
      'Retains activity against echinocandin-resistant Candida including C. auris',
      'Dual formulation (IV and oral) in development for hospital-to-home stepdown',
    ],
    weaknesses: [
      'FURI trial was single-arm open-label; no randomized comparator data for invasive indications',
      'Scynexis has limited commercial infrastructure; GSK partnership for ex-US rights',
      'Hepatotoxicity signals at higher doses required dose optimization for invasive indications',
    ],
    source: 'Scynexis pipeline 2024; ClinicalTrials.gov; FDA label 2021',
    last_updated: '2025-01-15',
  },

  // ── Mpox ──────────────────────────────────────────────────
  {
    asset_name: 'TPOXX',
    generic_name: 'tecovirimat',
    company: 'SIGA Technologies',
    indication: 'Mpox',
    indication_specifics:
      'FDA-approved for smallpox; CDC expanded access/emergency use for mpox (monkeypox) in outbreak settings',
    mechanism:
      'Inhibitor of orthopoxvirus VP37 envelope wrapping protein, blocking release of extracellular enveloped virions and preventing cell-to-cell spread',
    mechanism_category: 'antiviral_novel',
    molecular_target: 'VP37 (orthopoxvirus envelope protein)',
    phase: 'Approved',
    primary_endpoint: 'Time to lesion resolution',
    key_data:
      'STOMP trial: did not meet primary endpoint (time to lesion resolution) in randomized placebo-controlled trial in mpox; 18.9 vs 21.5 days (NS)',
    line_of_therapy: '1L',
    nct_ids: ['NCT05534984'],
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: [
      'Only FDA-approved antiviral for orthopoxvirus infections (smallpox label)',
      'Oral formulation enables outpatient treatment with established safety profile from animal efficacy studies',
      'Strategic national stockpile procurement provides guaranteed revenue base',
    ],
    weaknesses: [
      'STOMP trial failed primary endpoint in mpox raising questions about clinical benefit',
      'Approved via Animal Rule (efficacy from animal studies only); human efficacy unproven',
      'Resistance mutations in VP37 identified in treated mpox patients during 2022 outbreak',
    ],
    source: 'FDA label; STOMP trial; SIGA Technologies 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Brincidofovir',
    generic_name: 'brincidofovir',
    company: 'Chimerix',
    indication: 'Mpox',
    indication_specifics:
      'Phase 3 lipid conjugate of cidofovir for orthopoxvirus infections; FDA-approved for smallpox (Tembexa)',
    mechanism:
      'Lipid conjugate prodrug of cidofovir; intracellularly releases cidofovir diphosphate which inhibits viral DNA polymerase',
    mechanism_category: 'antiviral_dna_polymerase',
    molecular_target: 'Orthopoxvirus DNA polymerase',
    phase: 'Phase 3',
    primary_endpoint: 'Survival in animal models (smallpox label); lesion resolution in mpox',
    key_data:
      'FDA approved for smallpox (2021) via Animal Rule; oral formulation; reduced nephrotoxicity vs IV cidofovir',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: [
      'FDA-approved for smallpox providing regulatory pathway and manufacturing infrastructure',
      'Oral administration eliminates IV cidofovir nephrotoxicity through lipid prodrug design',
      'Broad antiviral spectrum against all double-stranded DNA viruses',
    ],
    weaknesses: [
      'GI toxicity (diarrhea, nausea) common and dose-limiting in clinical use',
      'Limited mpox-specific clinical data; efficacy extrapolated from animal models',
      'Chimerix has shifted strategic focus away from infectious disease',
    ],
    source: 'FDA label (Tembexa) 2021; Chimerix 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Jynneos',
    generic_name: 'Modified Vaccinia Ankara (MVA-BN)',
    company: 'Bavarian Nordic',
    indication: 'Mpox',
    indication_specifics:
      'FDA-approved for prevention of smallpox and mpox in adults at high risk; two-dose subcutaneous or intradermal regimen',
    mechanism:
      'Live, non-replicating Modified Vaccinia Ankara virus stimulating protective T-cell and antibody responses against orthopoxviruses',
    mechanism_category: 'vaccine_live_attenuated',
    molecular_target: 'Orthopoxvirus immune response',
    phase: 'Approved',
    primary_endpoint: 'Seroconversion rate and neutralizing antibody titers',
    key_data:
      'EUA during 2022 mpox outbreak: ~86% effectiveness (2 doses) preventing mpox infection; intradermal dosing extended supply 5-fold',
    line_of_therapy: '1L (prevention)',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'Only FDA-approved vaccine for mpox prevention with strong real-world effectiveness data',
      'Non-replicating platform safe for immunocompromised individuals unlike ACAM2000',
      'Intradermal dosing at 1/5 dose demonstrated equivalent immunogenicity, extending supply',
    ],
    weaknesses: [
      'Two-dose regimen with 28-day interval limits utility in outbreak response settings',
      'Limited global manufacturing capacity created significant supply shortages during 2022 outbreak',
      'Waning immunity necessitates booster dosing, optimal interval not yet defined',
    ],
    source: 'FDA label; Bavarian Nordic 2024; CDC MMWR effectiveness studies',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Cidofovir (Off-label)',
    generic_name: 'cidofovir',
    company: 'Generic (multiple)',
    indication: 'Mpox',
    indication_specifics:
      'Off-label IV antiviral for severe or disseminated mpox, particularly in immunocompromised patients',
    mechanism:
      'Acyclic nucleotide phosphonate analog that inhibits viral DNA polymerase after intracellular phosphorylation',
    mechanism_category: 'antiviral_dna_polymerase',
    molecular_target: 'Orthopoxvirus DNA polymerase',
    phase: 'Approved',
    primary_endpoint: 'CMV retinitis (labeled); mpox lesion resolution (off-label)',
    key_data:
      'Case series: anecdotal benefit in severe/disseminated mpox in immunocompromised patients; no controlled mpox-specific data',
    line_of_therapy: '2L+',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'Broad antiviral activity against all dsDNA viruses including orthopoxviruses',
      'Immediate availability as generic IV formulation for severe cases',
    ],
    weaknesses: [
      'Dose-limiting nephrotoxicity requiring probenecid co-administration and aggressive hydration',
      'IV-only administration requiring inpatient setting',
      'No randomized data supporting efficacy in mpox; purely empiric use based on in vitro activity',
    ],
    source: 'CDC mpox treatment guidelines 2023; off-label use reports',
    last_updated: '2025-01-15',
  },

  // ── Chronic Hepatitis D ───────────────────────────────────
  {
    asset_name: 'Hepcludex',
    generic_name: 'bulevirtide',
    company: 'Gilead Sciences',
    indication: 'Chronic Hepatitis D',
    indication_specifics:
      'EMA-approved (conditional) for treatment of chronic hepatitis delta virus (HDV) infection in adults with compensated liver disease',
    mechanism:
      'First-in-class entry inhibitor that blocks NTCP (sodium taurocholate co-transporting polypeptide) receptor, preventing HDV and HBV entry into hepatocytes',
    mechanism_category: 'antiviral_entry_inhibitor',
    molecular_target: 'NTCP (sodium taurocholate co-transporting polypeptide)',
    phase: 'Approved',
    primary_endpoint: 'HDV RNA decline >= 2 log10 or undetectable HDV RNA at Week 48',
    key_data:
      'MYR 301 Phase 3: 48% of patients achieved combined virologic and biochemical response at Week 48 vs 2% with delayed treatment',
    line_of_therapy: '1L',
    nct_ids: ['NCT03852719'],
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: [
      'First and only approved therapy specifically for chronic hepatitis D worldwide',
      'Novel entry inhibitor mechanism blocks both HDV and HBV hepatocyte entry',
      'Subcutaneous self-administration enables outpatient chronic treatment',
    ],
    weaknesses: [
      'Conditional approval in EU only; FDA approval still pending Phase 3 completion',
      'Daily subcutaneous injection for potentially indefinite duration burdens patients',
      'Bile acid elevation and pruritus from NTCP inhibition affect tolerability',
    ],
    source: 'EMA authorization; MYR 301 trial; Gilead 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Lonafarnib',
    generic_name: 'lonafarnib',
    company: 'Eiger BioPharmaceuticals',
    indication: 'Chronic Hepatitis D',
    indication_specifics:
      'Phase 3 oral prenylation inhibitor for chronic hepatitis D in combination with ritonavir (boosted)',
    mechanism:
      'Farnesyltransferase inhibitor blocking prenylation of large hepatitis delta antigen (L-HDAg), preventing HDV virion assembly and secretion',
    mechanism_category: 'antiviral_novel',
    molecular_target: 'Farnesyltransferase (L-HDAg prenylation)',
    phase: 'Phase 3',
    primary_endpoint: 'HDV RNA decline >= 2 log10 or undetectable at Week 48',
    key_data:
      'D-LIVR Phase 3: lonafarnib + ritonavir achieved >2 log decline in HDV RNA in ~35% of patients; GI tolerability limiting',
    line_of_therapy: '1L',
    nct_ids: ['NCT03719313'],
    partner: 'Ritonavir boosting (AbbVie/generic)',
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: [
      'Oral administration provides convenience advantage over bulevirtide daily injections',
      'First-in-class prenylation inhibitor mechanism complementary to entry inhibitors for potential combinations',
      'Eiger dedicated solely to hepatitis D creating focused development strategy',
    ],
    weaknesses: [
      'Significant GI toxicity (nausea, diarrhea, weight loss) affects tolerability and compliance',
      'Requires ritonavir boosting adding CYP3A4 drug interaction burden',
      'Eiger filed for bankruptcy in 2023; future development uncertain without new sponsor',
    ],
    source: 'Eiger BioPharmaceuticals; D-LIVR trial; ClinicalTrials.gov',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'PEG-Interferon Lambda',
    generic_name: 'peginterferon lambda-1a',
    company: 'Eiger BioPharmaceuticals',
    indication: 'Chronic Hepatitis D',
    indication_specifics:
      'Phase 3 investigation as subcutaneous interferon with improved tolerability over peginterferon alfa for HDV',
    mechanism:
      'Type III interferon (IL-29) signaling through IL-28R/IL-10R2 receptor complex; induces antiviral ISGs with restricted receptor distribution reducing systemic side effects',
    mechanism_category: 'immunomodulator_interferon',
    molecular_target: 'IL-28R1/IL-10R2 (type III interferon receptor)',
    phase: 'Phase 3',
    primary_endpoint: 'HDV RNA undetectable or >= 2 log10 decline at end of treatment',
    key_data:
      'LIMT-2 Phase 2: 36% achieved >= 2 log HDV RNA decline vs 0% placebo at Week 48; better tolerated than peg-IFN alfa',
    line_of_therapy: '1L',
    nct_ids: ['NCT05070364'],
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: [
      'Lambda interferon receptor expression restricted to hepatocytes reducing flu-like symptoms and cytopenias vs alfa',
      'Finite treatment duration (48 weeks) unlike bulevirtide indefinite dosing',
      'Potential for functional cure (sustained off-treatment HDV RNA suppression) in subset of patients',
    ],
    weaknesses: [
      'Interferon class still carries tolerability burden including injection site reactions',
      'Eiger bankruptcy creates development uncertainty for this program',
      'Transaminase flares during treatment require monitoring and may represent immune-mediated hepatitis',
    ],
    source: 'Eiger BioPharmaceuticals; LIMT-2 trial; ClinicalTrials.gov',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'REP 2139-Ca',
    generic_name: 'REP 2139-Ca',
    company: 'Replicor Inc.',
    indication: 'Chronic Hepatitis D',
    indication_specifics:
      'Phase 2 nucleic acid polymer (NAP) for chronic hepatitis D targeting HBsAg release for functional cure',
    mechanism:
      'Nucleic acid polymer (NAP) blocking subviral particle assembly and secretion of HBsAg, enabling immune restoration against HBV/HDV',
    mechanism_category: 'antiviral_novel',
    molecular_target: 'HBsAg assembly/secretion',
    phase: 'Phase 2',
    primary_endpoint: 'HBsAg seroconversion and HDV RNA clearance',
    key_data:
      'REP 401 Phase 2: REP 2139-Ca + peg-IFN alfa achieved HBsAg loss in ~40% and HDV RNA clearance in ~50% of patients at 1-year follow-up',
    line_of_therapy: '1L',
    nct_ids: ['NCT02876419'],
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: [
      'First-in-class NAP technology targeting HBsAg clearance, the prerequisite for functional cure',
      'Remarkable HBsAg seroconversion rates (~40%) unprecedented for any HBV/HDV therapy',
      'Potential for off-treatment sustained response (functional cure) unlike suppressive therapies',
    ],
    weaknesses: [
      'Weekly IV infusions for 48 weeks create substantial treatment burden',
      'Infusion-related reactions including transaminase flares observed during HBsAg decline',
      'Replicor is a small Canadian biotech with limited resources for global Phase 3 development',
    ],
    source: 'Replicor pipeline 2024; REP 401 trial; Bazinet et al. Lancet Gastro Hepatol 2020',
    last_updated: '2025-01-15',
  },

  // ══════════════════════════════════════════════════════════
  // PULMONOLOGY GAPS
  // ══════════════════════════════════════════════════════════

  // ── Sarcoidosis ───────────────────────────────────────────
  {
    asset_name: 'Prednisone (Standard of Care)',
    generic_name: 'prednisone',
    company: 'Generic (multi-manufacturer)',
    indication: 'Sarcoidosis',
    indication_specifics: 'First-line pharmacotherapy for symptomatic pulmonary and extrapulmonary sarcoidosis',
    mechanism:
      'Systemic corticosteroid suppressing granulomatous inflammation via glucocorticoid receptor-mediated immunosuppression',
    mechanism_category: 'corticosteroid',
    molecular_target: 'Glucocorticoid receptor',
    phase: 'Approved',
    primary_endpoint: 'FVC change and symptom improvement',
    key_data:
      'Standard of care for >50 years; initial response in ~80% of patients; no FDA-approved therapy specifically for sarcoidosis exists',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'Rapid symptom relief and radiographic improvement in majority of patients',
      'Decades of clinical experience with well-understood pharmacology',
      'Ultra-low cost and global availability',
    ],
    weaknesses: [
      'No FDA-approved therapy; all use is off-label or empiric for sarcoidosis',
      'Chronic steroid side effects (diabetes, osteoporosis, adrenal suppression) limit long-term use',
      'Relapse occurs in ~50% of patients upon steroid taper, creating steroid dependence',
    ],
    source: 'ATS/ERS/WASOG sarcoidosis guidelines 2020; clinical practice',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Namilumab',
    generic_name: 'namilumab',
    company: 'Kiniksa Pharmaceuticals',
    indication: 'Sarcoidosis',
    indication_specifics: 'Phase 2 anti-GM-CSF monoclonal antibody for chronic pulmonary sarcoidosis',
    mechanism:
      'Anti-GM-CSF monoclonal antibody blocking granulocyte-macrophage colony-stimulating factor, a key cytokine driving granuloma formation and macrophage activation',
    mechanism_category: 'monoclonal_antibody_targeted',
    molecular_target: 'GM-CSF',
    phase: 'Phase 2',
    primary_endpoint: 'Change in FVC and steroid-sparing effect',
    key_data:
      'Phase 2 ATLAS: preliminary data showed FVC improvement and steroid dose reduction in chronic pulmonary sarcoidosis patients',
    line_of_therapy: '2L+',
    nct_ids: ['NCT04902183'],
    first_in_class: true,
    orphan_drug: true,
    has_biomarker_selection: false,
    strengths: [
      'GM-CSF is directly implicated in granuloma biology providing strong mechanistic rationale',
      'Kiniksa focused development in auto-inflammatory diseases with regulatory expertise',
      'Potential to be first FDA-approved therapy specifically indicated for sarcoidosis',
    ],
    weaknesses: [
      'GM-CSF blockade may increase susceptibility to pulmonary infections',
      'Sarcoidosis is heterogeneous; responder identification challenging without validated biomarkers',
      'Phase 2 data not yet fully mature; efficacy signal requires confirmation',
    ],
    source: 'Kiniksa pipeline 2024; ClinicalTrials.gov; ATLAS study',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Efzofitimod',
    generic_name: 'efzofitimod',
    company: 'Teva Pharmaceuticals',
    indication: 'Sarcoidosis',
    indication_specifics:
      'Phase 2 anti-inflammatory fusion protein for chronic non-infectious uveitis and pulmonary sarcoidosis',
    mechanism:
      'Neuropilin-2 (NRP2)-targeting Fc fusion protein that modulates macrophage and T-cell inflammatory responses at granuloma sites',
    mechanism_category: 'immunomodulator_novel',
    molecular_target: 'NRP2 (neuropilin-2) pathway',
    phase: 'Phase 2',
    primary_endpoint: 'Steroid-sparing effect and pulmonary function improvement',
    key_data:
      'Phase 2 PRECIS: efzofitimod demonstrated significant steroid-sparing effect in pulmonary sarcoidosis vs placebo',
    line_of_therapy: '2L+',
    nct_ids: ['NCT04584671'],
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'Novel NRP2-targeting mechanism distinct from broad immunosuppression approaches',
      'Teva large-pharma resources for global development and commercial execution',
      'Steroid-sparing primary endpoint aligns with highest unmet need in sarcoidosis',
    ],
    weaknesses: [
      'NRP2 pathway in sarcoidosis not as well-validated as GM-CSF or TNF-alpha targets',
      'IV infusion requirement limits convenience versus oral alternatives',
      'Sarcoidosis clinical trial design challenges (heterogeneous disease, variable course)',
    ],
    source: 'Teva pipeline 2024; ClinicalTrials.gov; PRECIS study',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Nerandomilast',
    generic_name: 'nerandomilast (BI 1015550)',
    company: 'Boehringer Ingelheim',
    indication: 'Sarcoidosis',
    indication_specifics:
      'Phase 2 investigation of preferential PDE4B inhibitor for pulmonary sarcoidosis with fibrotic component',
    mechanism:
      'Preferential PDE4B inhibitor reducing inflammatory cytokine production while sparing PDE4D (emesis pathway), improving tolerability over non-selective PDE4 inhibitors',
    mechanism_category: 'pde4_inhibitor',
    molecular_target: 'PDE4B',
    phase: 'Phase 2',
    primary_endpoint: 'Change in FVC from baseline',
    key_data:
      'Phase 2 in IPF showed FVC benefit; sarcoidosis-specific investigation exploring anti-inflammatory and anti-fibrotic dual activity',
    line_of_therapy: '2L+',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'PDE4B selectivity reduces GI side effects that plagued earlier PDE4 inhibitors (roflumilast)',
      'Dual anti-inflammatory and anti-fibrotic mechanism addresses both phases of sarcoidosis',
      'Boehringer has deep ILD expertise from nintedanib development and commercial success',
    ],
    weaknesses: [
      'PDE4 inhibition is a known mechanism; differentiation versus existing immunosuppressants unclear',
      'Sarcoidosis cohort is expansion from ILD program; not specifically designed for sarcoidosis',
      'Oral PDE4 inhibitors still carry residual GI and psychiatric adverse event risk',
    ],
    source: 'Boehringer Ingelheim pipeline 2024; ClinicalTrials.gov',
    last_updated: '2025-01-15',
  },

  // ── Allergic Bronchopulmonary Aspergillosis ───────────────
  {
    asset_name: 'Itraconazole (Standard of Care)',
    generic_name: 'itraconazole',
    company: 'Generic (multi-manufacturer)',
    indication: 'Allergic Bronchopulmonary Aspergillosis',
    indication_specifics:
      'Off-label first-line antifungal treatment for ABPA to reduce Aspergillus fungal burden and steroid dependence',
    mechanism:
      'Triazole antifungal inhibiting lanosterol 14-alpha-demethylase (CYP51) in Aspergillus, blocking ergosterol synthesis and fungal growth',
    mechanism_category: 'antifungal_azole',
    molecular_target: 'CYP51 (lanosterol 14-alpha-demethylase)',
    phase: 'Approved',
    primary_endpoint: 'Total serum IgE reduction and steroid-sparing effect',
    key_data:
      'Randomized trials: itraconazole reduces total IgE by ~25%, enables steroid reduction in ~60% of ABPA patients; 16-week courses standard',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'Decades of evidence supporting antifungal therapy in ABPA management',
      'Generic availability ensures low cost and broad access',
      'Reduces total IgE and enables meaningful corticosteroid dose reduction',
    ],
    weaknesses: [
      'Erratic oral bioavailability requiring therapeutic drug monitoring',
      'Significant CYP3A4 inhibition creating numerous drug interactions',
      'Hepatotoxicity risk and QTc prolongation limiting use in cardiac patients',
    ],
    source: 'ISHAM/ABPA guidelines; Agarwal et al. Cochrane 2019',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Xolair',
    generic_name: 'omalizumab',
    company: 'Genentech/Novartis',
    indication: 'Allergic Bronchopulmonary Aspergillosis',
    indication_specifics:
      'Off-label anti-IgE therapy for ABPA in patients with asthma or cystic fibrosis to reduce exacerbations',
    mechanism:
      'Recombinant humanized anti-IgE monoclonal antibody that binds free IgE, preventing IgE-mediated mast cell degranulation and allergic inflammation',
    mechanism_category: 'monoclonal_antibody_targeted',
    molecular_target: 'IgE',
    phase: 'Phase 2',
    primary_endpoint: 'Exacerbation rate and total IgE reduction',
    key_data:
      'Case series and retrospective studies: ~70% response rate in steroid-dependent ABPA; reduces exacerbation frequency by ~50%; prospective Phase 2 data emerging',
    line_of_therapy: '2L+',
    nct_ids: ['NCT04442269'],
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: [
      'Directly targets IgE, the central mediator of Aspergillus-driven allergic pathophysiology in ABPA',
      'Extensive real-world evidence supporting efficacy in ABPA across multiple case series',
      'Well-established safety profile from decades of allergic asthma use',
    ],
    weaknesses: [
      'Off-label use without dedicated ABPA randomized controlled trial data for payers',
      'Very high IgE levels in ABPA may exceed dosing range creating underdosing',
      'High cost (~$30K/year) with limited ABPA-specific payer coverage policies',
    ],
    source: 'Genentech/Novartis; ISHAM ABPA guidelines; case series literature',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Dupixent',
    generic_name: 'dupilumab',
    company: 'Regeneron/Sanofi',
    indication: 'Allergic Bronchopulmonary Aspergillosis',
    indication_specifics:
      'Investigational Phase 2 anti-IL-4/IL-13 therapy for ABPA in asthma and cystic fibrosis patients',
    mechanism:
      'Monoclonal antibody blocking IL-4 receptor alpha subunit, inhibiting both IL-4 and IL-13 type 2 inflammatory signaling driving Th2-mediated ABPA pathology',
    mechanism_category: 'monoclonal_antibody_targeted',
    molecular_target: 'IL-4R alpha (IL-4/IL-13)',
    phase: 'Phase 2',
    primary_endpoint: 'Total IgE reduction and exacerbation rate',
    key_data:
      'Case reports and small series: dramatic IgE reduction (>50%) and clinical improvement in steroid-refractory ABPA; formal Phase 2 ongoing',
    line_of_therapy: '2L+',
    nct_ids: ['NCT04442256'],
    partner: 'Sanofi',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: [
      'Upstream Th2 blockade addresses multiple pathways simultaneously (IgE, eosinophilia, mucus)',
      'Case series show dramatic responses in steroid-refractory ABPA patients',
      'Already approved for asthma and atopic conditions with overlapping ABPA comorbidity',
    ],
    weaknesses: [
      'No completed randomized ABPA trial; efficacy data limited to case reports',
      'Theoretical concern that IL-4/IL-13 blockade could impair anti-fungal immune defense',
      'High drug cost (~$37K/year) with ABPA not in current approved indications',
    ],
    source: 'Regeneron/Sanofi pipeline 2024; ClinicalTrials.gov; case reports in JACI 2022',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Fasenra',
    generic_name: 'benralizumab',
    company: 'AstraZeneca',
    indication: 'Allergic Bronchopulmonary Aspergillosis',
    indication_specifics: 'Phase 2 investigation of anti-IL-5 receptor alpha antibody for eosinophilic ABPA',
    mechanism:
      'Anti-IL-5 receptor alpha monoclonal antibody with enhanced ADCC causing direct depletion of eosinophils and basophils',
    mechanism_category: 'monoclonal_antibody_targeted',
    molecular_target: 'IL-5R alpha',
    phase: 'Phase 2',
    primary_endpoint: 'Total IgE change and eosinophil reduction',
    key_data:
      'Case series: near-complete eosinophil depletion in ABPA patients with clinical improvement; formal Phase 2 data pending',
    line_of_therapy: '2L+',
    nct_ids: ['NCT04108962'],
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: [
      'Near-complete eosinophil depletion via ADCC mechanism is more potent than IL-5 ligand blockade (mepolizumab)',
      'Q8W subcutaneous dosing offers convenience advantage',
      'AstraZeneca respiratory franchise provides strong commercial infrastructure',
    ],
    weaknesses: [
      'Targets eosinophils only; may not address IgE-mediated and Th2 components of ABPA fully',
      'Less comprehensive type 2 blockade compared to dupilumab which targets IL-4/IL-13',
      'No dedicated ABPA pivotal trial planned; dependent on investigator-initiated studies',
    ],
    source: 'AstraZeneca pipeline 2024; ClinicalTrials.gov; case reports',
    last_updated: '2025-01-15',
  },

  // ── Interstitial Lung Disease ─────────────────────────────
  {
    asset_name: 'Ofev',
    generic_name: 'nintedanib',
    company: 'Boehringer Ingelheim',
    indication: 'Interstitial Lung Disease',
    indication_specifics:
      'FDA-approved for IPF, SSc-ILD, and chronic fibrosing ILDs with progressive phenotype (PF-ILD)',
    mechanism:
      'Triple angiokinase inhibitor targeting VEGFR, FGFR, and PDGFR; inhibits fibroblast proliferation, migration, and extracellular matrix production',
    mechanism_category: 'small_molecule_tki',
    molecular_target: 'VEGFR/FGFR/PDGFR',
    phase: 'Approved',
    primary_endpoint: 'Annual rate of FVC decline',
    key_data:
      'INBUILD (PF-ILD): reduced FVC decline by 57% (-80.8 vs -187.8 mL/year, p<0.001); SENSCIS (SSc-ILD): reduced FVC decline by 44%',
    line_of_therapy: '1L',
    nct_ids: ['NCT02999178'],
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'Broadest ILD label covering IPF, SSc-ILD, and progressive fibrosing ILD phenotype',
      'Consistent 44-57% reduction in FVC decline across multiple ILD etiologies',
      'Boehringer dominant commercial position in ILD therapeutic area',
    ],
    weaknesses: [
      'Significant GI toxicity (diarrhea in ~67%) requiring dose reduction or discontinuation',
      'Slows but does not halt or reverse fibrosis progression',
      'Hepatotoxicity risk requiring liver function monitoring every 3 months',
    ],
    source: 'FDA label; INBUILD and SENSCIS trials; Boehringer 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Nerandomilast',
    generic_name: 'nerandomilast (BI 1015550)',
    company: 'Boehringer Ingelheim',
    indication: 'Interstitial Lung Disease',
    indication_specifics:
      'Phase 3 preferential PDE4B inhibitor for IPF and PF-ILD, as monotherapy and combination with nintedanib',
    mechanism:
      'Preferential PDE4B inhibitor with anti-inflammatory and anti-fibrotic dual activity; suppresses fibroblast activation and TGF-beta signaling',
    mechanism_category: 'pde4_inhibitor',
    molecular_target: 'PDE4B',
    phase: 'Phase 3',
    primary_endpoint: 'Annual rate of FVC decline',
    key_data:
      'Phase 2 FLORA: numerical FVC improvement (+5.7 mL/12 weeks) with nerandomilast vs decline (-81.7 mL) with placebo; Phase 3 FIBRONEER enrolling',
    line_of_therapy: '1L and combination',
    nct_ids: ['NCT05321069'],
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'Phase 2 FLORA showed FVC stabilization/improvement unlike any prior ILD therapy (slowing decline only)',
      'PDE4B selectivity significantly reduces GI side effects compared to non-selective PDE4 inhibitors',
      'Oral once-daily dosing; potential combination with nintedanib for additive benefit',
    ],
    weaknesses: [
      'Phase 2 was small (n=147) with wide confidence intervals; Phase 3 confirmation critical',
      'Boehringer developing both nintedanib and nerandomilast may create internal portfolio tension',
      'PDE4B inhibition mechanism of action in fibrosis requires further mechanistic validation',
    ],
    source: 'Boehringer Ingelheim pipeline 2024; FLORA trial; ClinicalTrials.gov',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Bexotegrast',
    generic_name: 'bexotegrast (PLN-74809)',
    company: 'Pliant Therapeutics',
    indication: 'Interstitial Lung Disease',
    indication_specifics: 'Phase 2 dual integrin inhibitor (alphavbeta6/alphavbeta1) for IPF and PF-ILD',
    mechanism:
      'Oral selective inhibitor of alphavbeta6 and alphavbeta1 integrins, blocking TGF-beta activation at the cell surface, the central pro-fibrotic pathway in lung fibrosis',
    mechanism_category: 'integrin_inhibitor',
    molecular_target: 'Integrin alphavbeta6 / alphavbeta1',
    phase: 'Phase 2',
    primary_endpoint: 'Change in FVC from baseline at Week 24',
    key_data:
      'Phase 2a INTEGRIS-IPF: dose-dependent FVC improvement up to +24 mL at Week 12 vs nintedanib-treated patients; biomarker (fragment F) reduction confirmed target engagement',
    line_of_therapy: '1L',
    nct_ids: ['NCT04396756'],
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: [
      'First-in-class integrin-targeted anti-fibrotic addressing upstream TGF-beta activation',
      'Oral administration with encouraging Phase 2a signal on FVC and fibrosis biomarkers',
      'Novel mechanism complementary to nintedanib enabling combination potential',
    ],
    weaknesses: [
      'Small Phase 2a study; dose-ranging Phase 2b required before pivotal trials',
      'Pliant is a clinical-stage biotech with no commercial infrastructure',
      'Integrin biology in lung fibrosis extrapolated from preclinical models; human validation still early',
    ],
    source: 'Pliant Therapeutics pipeline 2024; INTEGRIS-IPF trial; ClinicalTrials.gov',
    last_updated: '2025-01-15',
  },

  // ══════════════════════════════════════════════════════════
  // NEPHROLOGY GAPS
  // ══════════════════════════════════════════════════════════

  // ── Minimal Change Disease ────────────────────────────────
  {
    asset_name: 'Prednisone (Standard of Care)',
    generic_name: 'prednisone',
    company: 'Generic (multi-manufacturer)',
    indication: 'Minimal Change Disease',
    indication_specifics: 'First-line immunosuppressive therapy for adult MCD inducing remission of nephrotic syndrome',
    mechanism:
      'Systemic corticosteroid suppressing podocyte injury-driving immune dysregulation via glucocorticoid receptor-mediated T-cell and cytokine modulation',
    mechanism_category: 'corticosteroid',
    molecular_target: 'Glucocorticoid receptor',
    phase: 'Approved',
    primary_endpoint: 'Complete remission (proteinuria <0.3 g/day)',
    key_data:
      'Response rate ~80-90% in adults within 8-16 weeks; however ~50-75% relapse upon steroid taper requiring steroid-sparing agents',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'Very high initial remission rate of 80-90% establishing standard of care',
      'Low cost and universal availability',
      'Rapid onset of proteinuria reduction within weeks of initiation',
    ],
    weaknesses: [
      'High relapse rate (50-75%) upon taper creates steroid-dependent phenotype',
      'Cumulative steroid toxicity (osteoporosis, diabetes, cataracts) limits chronic use',
      'No approved steroid-sparing agent specifically for MCD; all alternatives off-label',
    ],
    source: 'KDIGO Glomerular Disease Guidelines 2021; clinical practice',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Rituximab (Off-label)',
    generic_name: 'rituximab',
    company: 'Roche/Genentech (and biosimilars)',
    indication: 'Minimal Change Disease',
    indication_specifics: 'Off-label anti-CD20 therapy for frequently relapsing or steroid-dependent MCD in adults',
    mechanism:
      'Anti-CD20 monoclonal antibody depleting B lymphocytes; proposed mechanism in MCD involves disruption of B-cell/T-cell crosstalk driving podocyte injury',
    mechanism_category: 'monoclonal_antibody_targeted',
    molecular_target: 'CD20',
    phase: 'Phase 2',
    primary_endpoint: 'Relapse-free survival at 12 months',
    key_data:
      'NEMO trial and case series: rituximab maintained remission in ~60-80% of steroid-dependent MCD patients at 1 year; significant steroid-sparing',
    line_of_therapy: '2L+',
    nct_ids: ['NCT03970577'],
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'Growing evidence base supporting sustained remission in steroid-dependent MCD',
      'Biosimilar availability reduces cost barrier for off-label nephrology use',
      'Well-characterized safety profile from decades of use in hematology and autoimmune disease',
    ],
    weaknesses: [
      'Off-label use without FDA-approved MCD indication; payer coverage inconsistent',
      'B-cell depletion carries infection risk (hypogammaglobulinemia) with repeated courses',
      'Relapse still occurs in 20-40% within 2 years requiring re-treatment cycles',
    ],
    source: 'NEMO trial; KDIGO guidelines 2021; nephrologist case series',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Lupkynis',
    generic_name: 'voclosporin',
    company: 'Aurinia Pharmaceuticals',
    indication: 'Minimal Change Disease',
    indication_specifics:
      'Phase 2 investigation in steroid-dependent or frequently relapsing MCD; approved for lupus nephritis',
    mechanism:
      'Novel calcineurin inhibitor with direct podocyte-stabilizing effects; inhibits calcineurin-mediated dephosphorylation of synaptopodin in podocytes',
    mechanism_category: 'calcineurin_inhibitor',
    molecular_target: 'Calcineurin / synaptopodin',
    phase: 'Phase 2',
    primary_endpoint: 'Complete remission maintenance and steroid-sparing',
    key_data:
      'Lupus nephritis (AURORA): renal response 41% vs 23% MMF; MCD-specific trial investigating enhanced calcineurin inhibitor with podocyte-direct effects',
    line_of_therapy: '2L+',
    nct_ids: ['NCT05765474'],
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'Dual mechanism: calcineurin inhibition for immunosuppression plus direct podocyte stabilization',
      'More predictable pharmacokinetics than tacrolimus; flat dose-exposure relationship eliminates TDM need',
      'Aurinia has nephrology-focused commercial infrastructure from lupus nephritis launch',
    ],
    weaknesses: [
      'Calcineurin inhibitor class nephrotoxicity risk with chronic dosing in already-vulnerable kidneys',
      'No MCD-specific efficacy data yet; extrapolating from lupus nephritis results',
      'Aurinia limited resources; acquired by Otsuka which may shift development priorities',
    ],
    source: 'Aurinia/Otsuka pipeline 2024; AURORA trial; ClinicalTrials.gov',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Tavneos',
    generic_name: 'avacopan',
    company: 'ChemoCentryx/Amgen',
    indication: 'Minimal Change Disease',
    indication_specifics: 'Phase 2 investigation of C5a receptor inhibitor for glomerular diseases including MCD',
    mechanism:
      'Oral selective C5a receptor (C5aR1) antagonist blocking complement-mediated inflammation in glomerular disease',
    mechanism_category: 'complement_inhibitor',
    molecular_target: 'C5aR1 (complement C5a receptor)',
    phase: 'Phase 2',
    primary_endpoint: 'Proteinuria reduction and remission rate',
    key_data:
      'ADVOCATE (ANCA vasculitis): superior sustained remission vs prednisone taper; MCD-specific data emerging from investigator-initiated studies',
    line_of_therapy: '2L+',
    nct_ids: ['NCT05504720'],
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: [
      'Oral administration with steroid-sparing mechanism addresses core MCD treatment challenge',
      'First-in-class C5aR inhibitor with established safety from ANCA vasculitis approval',
      'Amgen resources support expansion into adjacent glomerular disease indications',
    ],
    weaknesses: [
      'Complement pathway role in MCD pathogenesis less established than in other glomerulonephritides',
      'Hepatotoxicity signals in ANCA vasculitis trials require close LFT monitoring',
      'No MCD-specific randomized data; mechanism extrapolation from ANCA vasculitis is speculative',
    ],
    source: 'ChemoCentryx/Amgen pipeline 2024; ADVOCATE trial; ClinicalTrials.gov',
    last_updated: '2025-01-15',
  },

  // ── Membranous Nephropathy ────────────────────────────────
  {
    asset_name: 'Rituximab (Emerging Standard)',
    generic_name: 'rituximab',
    company: 'Roche/Genentech (and biosimilars)',
    indication: 'Membranous Nephropathy',
    indication_specifics:
      'Off-label anti-CD20 therapy becoming de facto standard for primary membranous nephropathy; targets anti-PLA2R antibody-producing B cells',
    mechanism:
      'Anti-CD20 monoclonal antibody depleting B cells responsible for producing pathogenic anti-PLA2R and anti-THSD7A autoantibodies causing podocyte injury',
    mechanism_category: 'monoclonal_antibody_targeted',
    molecular_target: 'CD20',
    phase: 'Phase 3',
    primary_endpoint: 'Complete or partial remission of proteinuria at 24 months',
    key_data:
      'MENTOR trial: rituximab non-inferior to cyclosporine at 24 months (60% vs 20% remission) with superior long-term remission maintenance',
    line_of_therapy: '1L and 2L+',
    nct_ids: ['NCT01180036'],
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: [
      'MENTOR trial demonstrated clear superiority over cyclosporine in sustained remission at 24 months',
      'Anti-PLA2R antibody serves as treatment response biomarker for immunologic remission monitoring',
      'Biosimilar availability significantly reduces cost enabling broader access',
    ],
    weaknesses: [
      'Still off-label for membranous nephropathy despite strong evidence; payer challenges persist',
      'Slow onset of proteinuria reduction (months) leaves patients at thrombotic risk during response lag',
      'Incomplete remission in ~40% of patients necessitates alternative or additional therapy',
    ],
    source: 'MENTOR trial (Fervenza et al. NEJM 2019); KDIGO 2021; nephrologist consensus',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Gazyva',
    generic_name: 'obinutuzumab',
    company: 'Roche/Genentech',
    indication: 'Membranous Nephropathy',
    indication_specifics:
      'Phase 3 investigation of type II anti-CD20 antibody for primary membranous nephropathy (GARNET trial)',
    mechanism:
      'Type II glycoengineered anti-CD20 monoclonal antibody with enhanced direct cell death and ADCC versus rituximab type I',
    mechanism_category: 'monoclonal_antibody_targeted',
    molecular_target: 'CD20',
    phase: 'Phase 3',
    primary_endpoint: 'Complete remission rate at Month 24',
    key_data:
      'GARNET Phase 3 ongoing: comparing obinutuzumab vs rituximab in PLA2R-positive membranous nephropathy; superior B-cell depletion kinetics expected',
    line_of_therapy: '1L',
    nct_ids: ['NCT04629248'],
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: [
      'Glycoengineered Fc with superior ADCC and direct B-cell killing vs rituximab in preclinical models',
      'GARNET is first head-to-head anti-CD20 trial in membranous nephropathy',
      'Roche nephrology franchise expansion leveraging existing glomerular disease expertise',
    ],
    weaknesses: [
      'Higher infusion-related reaction rates than rituximab observed in hematology indications',
      'Cost premium over rituximab biosimilars may limit adoption if superiority not demonstrated',
      'Phase 3 results not yet available; unclear if enhanced B-cell depletion translates to better renal outcomes',
    ],
    source: 'Roche pipeline 2024; GARNET trial; ClinicalTrials.gov',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Felzartamab',
    generic_name: 'felzartamab',
    company: 'MorphoSys/Human Immunology Biosciences',
    indication: 'Membranous Nephropathy',
    indication_specifics:
      'Phase 2 anti-CD38 monoclonal antibody for rituximab-resistant membranous nephropathy targeting antibody-secreting plasma cells',
    mechanism:
      'Anti-CD38 monoclonal antibody depleting long-lived plasma cells and plasmablasts that are CD20-negative and resistant to rituximab-mediated depletion',
    mechanism_category: 'monoclonal_antibody_targeted',
    molecular_target: 'CD38',
    phase: 'Phase 2',
    primary_endpoint: 'Anti-PLA2R antibody reduction and proteinuria response',
    key_data:
      'Phase 2: felzartamab achieved >90% reduction in anti-PLA2R antibodies in rituximab-refractory MN patients; proteinuria improvement observed',
    line_of_therapy: '3L+',
    nct_ids: ['NCT04733040'],
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: [
      'Targets CD38+ plasma cells responsible for sustained autoantibody production after rituximab failure',
      'Dramatic anti-PLA2R antibody reduction in rituximab-resistant patients demonstrates novel mechanism value',
      'Addresses critical unmet need in anti-CD20 refractory membranous nephropathy',
    ],
    weaknesses: [
      'CD38 is expressed on multiple immune cell types; broad depletion may increase infection risk',
      'Limited clinical experience in nephrology; safety profile extrapolated from multiple myeloma data',
      'MorphoSys acquired by Novartis; HI-Bio development plans may shift under new ownership',
    ],
    source: 'HI-Bio/MorphoSys pipeline 2024; ClinicalTrials.gov; ASN presentations 2023',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Benlysta',
    generic_name: 'belimumab',
    company: 'GSK',
    indication: 'Membranous Nephropathy',
    indication_specifics:
      'Phase 2 investigation of anti-BLyS antibody for primary membranous nephropathy; approved for lupus nephritis and SLE',
    mechanism:
      'Anti-BLyS (BAFF) monoclonal antibody reducing B-cell survival, maturation, and autoantibody production by blocking B-lymphocyte stimulator',
    mechanism_category: 'monoclonal_antibody_targeted',
    molecular_target: 'BLyS/BAFF',
    phase: 'Phase 2',
    primary_endpoint: 'Change in proteinuria and anti-PLA2R antibody levels',
    key_data:
      'Lupus nephritis (BLISS-LN): renal response 43% vs 32% standard; MN Phase 2: preliminary anti-PLA2R reduction with belimumab + rituximab combination',
    line_of_therapy: '2L+',
    nct_ids: ['NCT03949855'],
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: true,
    strengths: [
      'Complementary mechanism to rituximab: prevents B-cell reconstitution and new autoantibody production',
      'Approved for lupus nephritis providing established nephrology safety profile and reimbursement pathway',
      'GSK large-pharma resources and established nephrology commercial presence',
    ],
    weaknesses: [
      'Anti-BAFF mechanism slower onset than direct B-cell depletion; may require combination with rituximab',
      'No standalone MN efficacy; likely requires rituximab combination adding complexity and cost',
      'Autoimmune MN pathophysiology may differ from lupus nephritis reducing cross-indication extrapolation',
    ],
    source: 'GSK pipeline 2024; BLISS-LN trial; ClinicalTrials.gov',
    last_updated: '2025-01-15',
  },
];
